US20060060266A1 - Stent and method for manufacturing the stent - Google Patents
Stent and method for manufacturing the stent Download PDFInfo
- Publication number
- US20060060266A1 US20060060266A1 US11/216,222 US21622205A US2006060266A1 US 20060060266 A1 US20060060266 A1 US 20060060266A1 US 21622205 A US21622205 A US 21622205A US 2006060266 A1 US2006060266 A1 US 2006060266A1
- Authority
- US
- United States
- Prior art keywords
- stent
- struts
- bridges
- stent body
- carrying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B23—MACHINE TOOLS; METAL-WORKING NOT OTHERWISE PROVIDED FOR
- B23K—SOLDERING OR UNSOLDERING; WELDING; CLADDING OR PLATING BY SOLDERING OR WELDING; CUTTING BY APPLYING HEAT LOCALLY, e.g. FLAME CUTTING; WORKING BY LASER BEAM
- B23K26/00—Working by laser beam, e.g. welding, cutting or boring
- B23K26/36—Removing material
- B23K26/38—Removing material by boring or cutting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/88—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements formed as helical or spiral coils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91533—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/9155—Adjacent bands being connected to each other
- A61F2002/91558—Adjacent bands being connected to each other connected peak to peak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/009—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof magnetic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0028—Shapes in the form of latin or greek characters
- A61F2230/0054—V-shaped
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0018—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in elasticity, stiffness or compressibility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0071—Additional features; Implant or prostheses properties not otherwise provided for breakable or frangible
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0096—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers
- A61F2250/0098—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers radio-opaque, e.g. radio-opaque markers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B23—MACHINE TOOLS; METAL-WORKING NOT OTHERWISE PROVIDED FOR
- B23K—SOLDERING OR UNSOLDERING; WELDING; CLADDING OR PLATING BY SOLDERING OR WELDING; CUTTING BY APPLYING HEAT LOCALLY, e.g. FLAME CUTTING; WORKING BY LASER BEAM
- B23K2103/00—Materials to be soldered, welded or cut
- B23K2103/02—Iron or ferrous alloys
- B23K2103/04—Steel or steel alloys
- B23K2103/05—Stainless steel
Definitions
- the invention lies in the field of vascular stents.
- the invention is in the field of helical stents for peripheral arteries, the biliary tree, and other body lumens.
- Stents have been developed for use in various lumens of the body, including the biliary tree, venous system, peripheral arteries, and coronary arteries. Stents are used to open or hold open a lumen that has been blocked (occluded) or reduced in size (stenosed) by some disease process, such as atherosclerosis or cancer.
- Previously developed stents for use in the biliary, venous, and arterial systems have been of two broad classes: balloon-expanded and self-expanding. In both of these classes, stents have generally been made by two different techniques: either formed from wire or machined from a hollow tube. Other manufacturing techniques have been proposed, such as vacuum or chemical deposition of material or forming a tube of machined flat material, but those “exotic” methods have not been widely commercialized.
- Circumferential and helical are based upon a series of cylindrical bands joined longitudinally by bridges to make a tubular structure.
- Helical configurations include a continuous helical structure (typically made of an undulating pattern of struts and end-loops) with joining structures (referred to as “bridges”) joining adjacent turns of the helix to provide mechanical integrity to the tubular structure (to prevent unwinding, kinking, and buckling).
- DiMario demonstrates 15.0% restenosis versus 36.6% for stents with thin struts (50 microns, Multilink) versus thick struts (average of all stents evaluated with struts greater than or equal to 100 microns). DiMario also relates stent efficacy to “integrated cell size,” showing better results for the BX VELOCITY® stent with cells of 3.3 mm 2 versus stents with larger cell sizes.
- DiMario reports reduced neointimal hyperplasia for smaller struts (0.8 mm thickness for closely-spaced 125-micron struts versus 1.54 mm thickness for wider-spaced 200-micron struts). Because prior art stent designs have large gaps between stent parts, drug elution about these parts does not adequately cover all of the tissue within the bounds of the stent.
- M-D Ratio This ratio, which has the units of reciprocal inches, will be referred to herein as the M-D Ratio because the inventors were Mathis and Duerig.
- Mathis describes prior-art stents as having a ratio of about 200 and that their improved stent has an M-D Ratio of over 400.
- the M-D Ratio is determined by number of struts divided by strut length. For a given diameter stent, assuming “maximum-metal” configuration, which is typical for self-expanding stents, the number of struts around the circumference is inversely proportional to the strut width. Thus, the M-D Ratio is inversely proportional to the product of strut width and length.
- the self-expended stent of the present invention is suitable for use in peripheral arteries, the biliary tree, and other body lumens.
- it will be most advantageous for use in arteries where flexure is an important factor, such as iliac arteries and carotid arteries.
- the stent is particularly suitable for the application of drug-eluting coatings intended to reduce restenosis or for other therapies.
- the stent according to the present invention allows virtually all tissue within the coverage area of the stent to be in the elution areas.
- the stent provides tissue coverage so that no element of wall tissue is more than 350 microns to 400 microns away from the nearest strut. Such a configuration assures a short diffusion path from a strut covered with a drug-eluting agent to any portion of the tissue.
- a method for manufacturing a helical stent includes the steps of providing a stent body with a circumference, with struts disposed about the circumference in turns, and with bridges connecting the struts in adjacent ones of the turns, and, after at least partially expanding the stent body, removing some of the bridges.
- a method for implanting a stent including the steps of providing the helical stent, loading the stent at a stent delivery system, traversing the stent at the delivery system to an implantation site, and implanting the stent at the implantation site.
- the struts are formed in a helix.
- the removing step is carried out by polishing and cleaning the stent body in processes selected from at least one of the group consisting of chemical, mechanical, and electrochemical.
- the processes can include abrasive blasting, glass-bead honing, chemical etching, mechanical polishing, electrochemical polishing, grinding, shearing, and cutting.
- the stent body is radially compressed.
- the stent body after carrying out the removing step, can be crimped onto a balloon catheter. Thereafter, the stent body is retained in the crimped state for delivery to an implantation site.
- the stent body is chilled and radially compressed. Thereafter, the stent body is retained in a compressed state for delivery to an implantation site.
- the stent body is provided with connecting bridges and sacrificial bridges each connecting the struts in adjacent ones of the turns.
- all of the sacrificial bridges can be partially removed. Substantially all of the sacrificial bridges can be removed. Only connecting bridges can be present at the stent body after expansion.
- the stent body can have a diameter of between approximately 4 mm and approximately 12 mm and/or a length of between approximately 10 mm and approximately 250 mm.
- the stent body can have s-shaped struts disposed helically about the circumference along helical turns, the struts having straight portions and curved portions connecting at least some of respectively adjacent ones of the straight portions.
- the stent body can have a finished kerf width of less than 25 microns, in particular, a width of approximately 18 microns.
- the stent body can have a pre-cut tubing diameter of approximately 2 millimeters, a post-cut number of struts per turn equal to 46, a finished kerf width of approximately 18 microns, and a post-cut strut width of 119 microns.
- the bridges can have an initial curvature shape and expansion of the stent body is controlled to substantially retain all of the initial curvature shape of the bridges.
- implantation of the stent is in a blood vessel.
- the stent is expanded at the implantation site. If the stent is a balloon-expanding stent, then the stent is expanded with a balloon of a stent delivery system. If the stent is a self-expanding stent, then the stent is allowed to self-expand at the implantation site.
- the present invention relies on a helical configuration with much shorter struts and significantly higher number of struts around the circumference than the prior art.
- helical stent configurations according to the present invention are not limited to even-integral numbers of struts—as are “hoop” configurations taught by Mathis.
- odd-integral numbers of struts around the circumferential or even non-integral numbers of struts around the circumference are possible in the helical configuration of the present invention because there is no requirement for the struts to rejoin themselves to make complete hoops.
- a helical stent could have 31.567 struts per revolution, or any other arbitrary number.
- the smaller stents in a product family sharing the same preform configuration have smaller opening angles, of course, resulting in lower chronic outward force (COF) and lower radial resistive force (RRF) to collapse, because the effective bending-lever length is longer in struts with lower opening angles.
- COF chronic outward force
- RRF radial resistive force
- Mathis teaches M-D Ratios of over 400 and numbers of struts up to 32 or more but does not teach or suggest ratios of near or over eight-hundred (800), let alone over one thousand (1000). Mathis, specifically, does not mention what effects a much larger number of struts would have, and does not imply implementation of significantly shorter struts.
- an exemplary configuration for an 8 mm diameter stent incorporates 46 struts around the helical circumference and the struts have a length of approximately 0.99 mm (0.039 inches).
- the M-D Ratio for this exemplary configuration according to the present invention is, therefore, 1180—nearly three times the ratios taught in the prior art.
- Stents according to the present invention have new and unexpected properties, even though they require greater attention to opening angles (and, hence, have a more limited useful size range for a given configuration).
- the present invention gives an integrated cell size of 1.6 mm 2 per cell unit in an 8 mm diameter stent. In a configuration with bridges every three cell units, the total integrated cell size would be 4.8 mm 2 , which is proportionately smaller than that of the BX VELOCITY® 3 mm stent.
- configurations according to the present invention have much smaller openings when expanded and, particularly, when the expanded stent is flexed in bending.
- the substantially smaller openings result in greatly improved resistance to the passage of emboli through the stent wall.
- Stents according to the present invention Another characteristic of stents according to the present invention is a greatly increased flexibility and resistance to buckling in bending or torsion. Stents according to the present invention also have improved fatigue life in real-life applications, resulting from a large number of struts and bending segments to absorb irregular, localized deformations caused by the anatomy—as opposed to such local deformations being placed on a small number of struts and bending segments, which results in over-straining some of these elements.
- Stent configurations optimized for a particular expanded diameter will have struts as wide as possible, consistent with the maximum allowable strain during storage and compression.
- the result of such a criterion is that stent configurations according to the present invention, with a greater number of struts of shorter length and narrower width than prior art configurations, will allow greater bending deflections, resulting in greater possible opening angles. Constructing an expanded stent with greater allowed opening angles also results in a relatively shorter projected lever-arm length acting on the struts and bending segments when the stent is expanded in the anatomy. These shorter lever arms result in higher outward forces applied to the vessel walls when the stent is expanded.
- the present invention results in configurations that are optimized for a small range of expanded sizes, creating the need to have individualized configurations for each expanded size of stent.
- This approach deviates from the prior art and results in higher configuration and validation costs, but results in stents with significantly improved flexural and fatigue properties while, at the same time, providing optimized radial outward forces and collapse resistance for each size.
- stents made according to this invention are proportionately narrower and, hence, less stiff in bending (in proportion to the cube of the width of the struts) when compared to prior art stent designs.
- This decrement in stiffness may be offset by increasing the opening angle of the stent, as described elsewhere herein, but the reduced stiffness of the struts (and also the increased opening angles) results in a tendency for portions of the helix to buckle when subjected to the stresses and strains required to fully collapse the stent prior to insertion into its delivery system.
- stents made with series of seven or nine struts between bridges have a high tendency toward buckling when compressed; stents made with five struts between bridges have an intermediate tendency toward buckling when compressed; and, stents with only three struts between bridges have a low tendency toward buckling when compressed. It should be noted that this tendency toward buckling does not adversely affect the characteristics of the stent when expanded in the body, because the compressive strains experienced in the body are insufficient to cause the buckling seen during compression into the delivery system.
- stents with very low numbers of struts between bridges e.g., one or three
- they are very easy to fully compress do not have flexibility as great as that of stents with larger numbers of struts between bridges (e.g., seven or nine).
- there is a tradeoff between design choices which create a stent that is easy to compress versus choices which make the stent flexible stents made according to this invention, configured with an M-D ratio in the range of 1000, have the most favorable balance of flexibility and buckling during compression when the number of struts between bridges is in the range of three to five.
- FIG. 1 is a fragmentary, enlarged partially cross-sectional and partially plan view of a stent delivery system configured to implant a stent according to the invention in a vessel;
- FIG. 2 is a fragmentary, enlarged plan view of the stent of FIG. 1 expanded and implanted in the vessel;
- FIG. 3 is a fragmentary, enlarged plan view of a portion of a first embodiment of the stent of FIG. 1 ;
- FIG. 4 is a fragmentary, enlarged plan view of a portion of a second embodiment of the stent of FIG. 1 ;
- FIG. 5 is a fragmentary, enlarged plan view of a portion of the second embodiment of the stent of FIG. 4 with circular markers;
- FIG. 6 is a fragmentary, enlarged plan view of a portion of the first embodiment of the stent of FIG. 3 with flat-ended markers;
- FIG. 7 is a fragmentary, enlarged plan view of a further enlarged portion of the first embodiment of the stent of FIG. 3 with some sacrificial bridges removed;
- FIG. 8 is a fragmentary, side elevational view of a portion of an expanded stent according to the invention with a protruding bridge;
- FIG. 9 is a fragmentary, enlarged plan view of a further enlarged portion of the first embodiment of the stent of FIG. 7 with the sacrificial bridges having break points;
- FIG. 10 is a plan view of a flat cut pattern representing the laser-cutting path to be created around a circumference of tubing from which the stent according to the invention is to be created;
- FIG. 11 is a fragmentary, enlarged, perspective view from the side of a stent according to the invention.
- FIG. 12 is a fragmentary, further enlarged, perspective view of a portion of the stent of FIG. 11 ;
- FIG. 13 is a fragmentary, enlarged, perspective view from an end of the stent of FIG. 11 ;
- FIG. 14 is a fragmentary, further enlarged, perspective view of a portion of the stent of FIG. 13 ;
- FIG. 15 is a fragmentary, enlarged plan view of a portion of an expanded stent according to the invention illustrating a largest embolism area
- FIG. 16 is a fragmentary, enlarged plan view of a portion of a prior art stent illustrating a largest embolism area.
- FIG. 1 there is shown is a helical stent 1 according to the present invention fitted on a delivery catheter 20 of an exemplary delivery system 10 .
- the helical stent 1 is about to be implanted in a vessel 30 .
- the helical stent 1 is in its unexpanded state and loaded into/onto the delivery system 10 that has traveled to an implantation site.
- FIG. 2 illustrates the helical stent 1 implanted in the vessel 30 after being expanded, whether by a balloon of the catheter 20 or by self-expansion due to a shape memory of the material of the stent 1 .
- the helical stent 1 has proximal 2 and distal 3 ends—defined by a blood flow direction A.
- the helix of the stent 1 can be a single coil with one start at the proximal end that winds all the way to the distal end.
- Such a configuration is possible with the present invention because the helical stent 1 has very short struts, which will be explained in further detail below.
- Another configuration alternative usable with short struts is a multiple-helix configuration (shown in FIG. 2 ), where more than one helixed start is present, for example, a double-lead, a triple-lead, and so on.
- With an exemplary 8 mm size of the helical stent according to the present invention up to 4 leads are practical.
- FIGS. 3 and 4 show enlarged views of a portion of the body of the helical stent 1 of the present invention.
- Each turn 4 of the helix is formed, in a preferred embodiment, by a continuous repetition of s-shaped struts 5 throughout the length of the helix.
- the struts 5 have straight portions 6 and curved portions 7 connecting respectively adjacent straight portions 6 .
- Connecting bridges 8 have a width substantially similar to a width of the straight and curved portions 6 , 7 and connect adjacent turns 4 of the helix.
- Also connecting adjacent turns of the helix are sacrificial bridges 9 , which have a width smaller than a width of the straight and curved portions 6 , 7 . Both of the bridges 8 , 9 will be described in greater detail below.
- Stents 1 may be made according to the present invention with struts 5 that are aligned with the longitudinal axis 10 of the stent 1 , as shown in FIG. 3 , or the struts 5 may be aligned perpendicular to the helical direction 11 , as shown in FIG. 4 .
- the longitudinally aligned straight portions 6 of the struts 5 produce a stent 1 that requires lower force to deploy from a confining sleeve because there are no oblique, twisting, knife-edges to cut into or grip the sleeve.
- the struts 6 are not of equal length (there is an equal number of short and long struts) and, therefore, it is not possible to fully balance the flexibility of these struts to fully utilize the properties of the material used to build the stent 1 .
- the configuration shown in FIG. 4 with helically aligned straight portions 6 of the struts 5 has the advantage of equal strut lengths. This configuration, in comparison, has a higher friction when the stent 1 is engaged inside a deployment system.
- markers 12 are paddle-shaped (that is, having a substantially disk-like enlarged portion with a narrow extension that joins it to the structure of the stent), they may be attached to the ends of the 180-degree bending segments 7 (or to other locations on the bending segments 7 or straight portions 6 ).
- the marker portions 12 need not be paddle-shaped. They can merely be rod-shaped to extend away from either or both of the distal and proximal ends 2 , 3 of the stent 1 . These rods can be expanded for better seating in the vessel and, even with a smaller surface area as compared to the paddle-shaped markers, can still provide sufficient area for receiving indicators that allow for better imaging.
- the flat end provided by the paddle-shaped markers 12 of FIG. 6 facilitates pushing the stent 1 out of a deployment device (although a shaped pusher that conforms to the helical end of the stent could be used but is harder to manufacture and align).
- a pusher component of a delivery catheter exerts a (distally-directed) counter-force onto the proximal end of the stent while a covering sleeve is retracted from its position over the stent. As the covering sleeve is retracted relative to the stent and the pusher, the distal end of the stent is exposed and, therefore, expands to contact the interior of the vessel.
- the paddle shaped markers 12 described above can be spaced from the helical end of the stent by narrow connectors as shown in FIGS. 5 and 6 , or by full-width connectors (i.e., markers that are of uniform width from their ends to the point where they join the struts or loops of the stent), or by directly connecting them to the other elements of the stent.
- FIG. 5 illustrates three paddle-shaped markers 12 attached by narrow connectors to the helical end of a portion of a stent 1 .
- paddle-shaped markers 12 While the disk-like enlarged portions of paddle-shaped markers 12 can be rounded, it is preferable for the extreme outer ends to be relatively straight. As such, the paddle-shaped markers 12 may be provided with non-circular ends 13 to facilitate engagement of the pushing device of the deployment catheter with which the stent is implanted. For example, FIG. 6 shows flat-ended paddle-shaped markers 12 that maximize contact between the paddles and the pushing device.
- the paddle-shaped markers 12 may be used to help anchor the stent 1 during and after deployment.
- the paddles may be radially expanded further than the struts 5 , 6 , 7 so that they form a funnel-shaped end to the stent 1 once expanded.
- radiopaque materials such as tungsten, tantalum, molybdenum, platinum, or gold
- inserted cylinders of tantalum 0.50 millimeters in diameter and having a thickness equal to or less than that of the marker paddles may be pressed, glued, riveted, threaded, or otherwise attached into holes or depressions formed in the paddles.
- connecting bridges 8 that connect adjacent turns or columns of struts 4 to provide the desirable overall stent flexibility as well as structural integrity. It is advantageous to form these bridges 8 in a substantially circumferential direction, as shown in FIG. 7 . Two advantageous characteristics emerge by so forming the connecting bridges 8 .
- the vertical (circumferential) offset caused by the bridges 8 ensures that, after expansion, the adjacent 180-degree bending segments (the vertices of the expanded strut pairs) are offset from one another and, thus, will interdigitate, allowing the stent 1 to bend easily.
- these circumferential bridges 8 are curved sharply in the plane perpendicular to the axis 10 of the stent 1 , which curvature results from the stent 1 being formed from small-diameter tubing.
- these bridges 8 extend radially away from the cylindrical surface of the stent 1 and present edges perpendicular to the axis 10 of the stent 1 .
- these features engage the vessel or body lumen wall 30 , preventing migration of the stent 1 .
- the enlargement of a bridge 8 in FIG. 8 illustrates how these structures protrude beyond the wall of a stent 1 in this manner.
- radiopaque materials such as gold, tantalum, zirconium oxide, barium and bismuth salts, hafnium, molybdenum, etc.
- the present invention is suitable for incorporating such markers, especially at the location of the paddles 12 , 13 , as described above.
- fiducial markers In addition to the prior-art use of radiopaque markers, it is possible to use other types of fiducial markers to enable placement, deployment, and subsequent location and diagnosis of the stent 1 .
- other non-illustrated markers can be made that are easily imaged by ultrasound, such as abraded surfaces, holes, voids, porous materials and coatings, hollow balloons, and layered materials of different sonic properties, to name a few.
- a hole 0.50 millimeters in diameter may be filled with a composite consisting of glass microballoons and tungsten powder suspended in an epoxy matrix.
- Such a composite marker would be highly visible under ultrasound imaging as well as x-ray imaging.
- markers having varying textures have improved anchoring characteristics.
- Magnetic resonance imaging may be enhanced by inclusion of paramagnetic, diamagnetic, and ferromagnetic materials that locally change the magnetic-field-producing spin-energy transitions in odd-number nuclei such as hydrogen, carbon-13, fluorine-19, and other nuclides known to those skilled in the art of magnetic resonance imaging.
- odd-number nuclei such as hydrogen, carbon-13, fluorine-19, and other nuclides known to those skilled in the art of magnetic resonance imaging.
- gadolinium or gadolinium salts (paramagnetic) provide visible changes to the image formed by hydrogen nuclei in their vicinity, thus, such materials can be incorporated into fiducial markers.
- Nano-scale ferromagnetic materials, such as hematite or other oxides can also provide useful MRI artifacts without troublesome image distortion.
- Magnetically active elements, salts, and compounds can be incorporated individually or in combination with other marker materials, such as radiopaque materials or ultrasound-visible structures or materials, to make multi-mode markers.
- Composite markers may contain materials with magnetic properties suitable to present fiducial marks on images made by magnetic resonance imaging (MRI) as well as other imaging modalities. Examples include combinations of radiopaque materials (such as, tungsten powder, zirconium oxide, bismuth subcarbonate, and gold powder), magnetically active materials such as diamagnetic or ferromagnetic materials (including gadolinium foil and powder, gadolinium salts, nanocrystalline iron oxide, and iron powder, for example), and ultrasonically visible material such as glass or ceramic microballoons.
- radiopaque materials such as, tungsten powder, zirconium oxide, bismuth subcarbonate, and gold powder
- magnetically active materials such as diamagnetic or ferromagnetic materials (including gadolinium foil and powder, gadolinium salts, nanocrystalline iron oxide, and iron powder
- the standard method for manufacturing machined tubular metal stents is to begin with a small-diameter metallic tube, typically, of stainless steel, platinum alloy, or chromium-cobalt alloy for balloon-expanded stents and of a nickel-titanium alloy for self-expanding stents.
- This tubing is mounted in a laser machining system that rotates the part around a stationary axis so that the focal point of a laser beam impinges upon the surface of the tube.
- a coaxial jet of gas either air, oxygen, or an inert gas such as argon
- the material is perforated by the laser energy (and possibly assisted by chemical reaction with air or oxygen).
- the tubing is moved under the laser beam in at least two axes, rotational and longitudinal, so that a continuous cut (or kerf) is made while the laser energy is applied.
- the laser beam is switched on and off under computer control in coordination with the longitudinal and rotational motions so that a discontinuous pattern of cuts is applied to the tubing.
- the tubing is further processed to produce either a balloon-expandable or a self-expanding stent.
- the laser-cut tubing preform is polished and cleaned using a combination of chemical, mechanical, and electrochemical measures to produce a finished stent that is, then, for example, crimped onto a balloon catheter.
- the laser-cut tubing is expanded by forcing it onto a succession of larger and larger mandrels. At each step of expansion, the tubing is subjected to an appropriate heat-treating step to thermally set the expanded step.
- nickel-titanium tubing may be heat treated at 480 degrees Celsius (480° C./896° F.) for thirty seconds while expanded on a mandrel to set that stage of expansion.
- 480° C./896° F. 480 degrees Celsius
- two to six expansion stages are necessary to fully expand a nickel-titanium self-expanding stent.
- the stent is finished by a combination of chemical, mechanical, and electrochemical polishing to produce a smooth, biocompatible surface suitable for implantation.
- the finished stent is, then, chilled (to transform it to the soft and deformable martensitic condition) and compressed radially to a size small enough to be placed into catheter of the stent delivery system.
- One manufacturing problem that must be overcome with self-expanding stents having the fine structures as described in the present invention is uneven opening occurring during thermo-mechanical expansion of the as-cut tubing to the final, expanded stent.
- the standard manufacturing process involves stretching the laser-cut stent over progressively larger tapered-end cylindrical mandrels and heat-treating the material at several stages while supported by these mandrels.
- the stent can be expanded by stretching it onto the successive expansion mandrels either at a low temperature (in the soft, martensitic condition) or at ambient temperature (in the springy, austenitic condition).
- the stent is exposed for a short period (several seconds to a few minutes) of high temperature, typically in the 450 to 500 Celsius range, to “shape-set” or anneal the stent at that level of expansion.
- Over-straining is most commonly seen as a pair of struts having an unusually large opening angle at their vertex relative to the angle of other strut pairs in the vicinity.
- This condition must be controlled and identified by in-process inspection because it may be hidden by later expansion steps and because it is an inherently unstable condition. That is, during a given expansion step, once a pair of struts begins to open excessively, that vertex becomes weakened, and the opening strains tend to be further concentrated on that particular pair of struts, so that it becomes progressively more over-strained.
- the present invention provides a process for preventing this local over-straining.
- the present invention as compared to the original number of bridges 8 , 9 originally existing between adjacent columns (or helical turns) of strut pairs in the unfinished stent, only a few bridges 8 exist in the finished stent, which remaining bridges 8 provide the desired flexibility and resistance to fatigue.
- additional sacrificial bridges 9 connect the bending segments joining strut pairs in adjacent turns or columns.
- sacrificial bridges 9 provides these additional connections and causes the expansion strains to be much more evenly shared by all the elements of the stent, which sharing results in a significant increase in the evenness of strains during expansion. The result is an expanded stent with vertex opening angles that have much less variation.
- the sacrificial bridges 9 substantially reduce the flexural (bending) flexibility of the stent 1 . Thus, they must be removed prior to finishing the stent 1 .
- These sacrificial bridges 9 may be removed at any stage after expansion, but, preferably, they are removed immediately after the final expansion heat-treating step, prior to any material-removal or polishing steps, so that any burrs left by removal will be reduced or eliminated during the polishing steps.
- the sacrificial bridges 9 may be removed after some of the expansion stages, but prior to one or more final expansion stage because it has been found that, once the stent 1 has been partially expanded in a very even manner, subsequent expansion steps do not generally introduce unevenness among the opening angles. In any case, it is only necessary to remove the extra, sacrificial bridges 9 at some point prior to implantation so that the finished stent 1 has the desired flexibility in its final, implanted form.
- sacrificial bridges 9 To facilitate removal of the sacrificial bridges 9 , special features can be engineered into the as-cut structure to provide prescribed locations for cutting or breaking the sacrificial bridges 9 . These features are illustrated in FIG. 9 as, for example, notches 14 formed at one or both of the ends of the sacrificial bridges 9 connected to the struts of adjacent turns 4 . While providing notches 14 is only one example to form the cutting/breaking location, alternative exemplary methods of removing sacrificial bridges include chemical etching, abrasive blasting, grinding, electrochemical etching or polishing, shearing, or laser cutting.
- stents are finished by a combination of abrasive blasting, glass-bead honing, chemical etching, mechanical polishing, and electrochemical polishing. All of these processes assist removal of any remaining burr left by the removal of the sacrificial bridges 9 .
- other measures such as grinding, shearing, mechanical polishing, and cutting may be used to locally smooth and remove burrs left by the sacrificial bridges 9 .
- FIG. 10 illustrates a flat cut pattern representing the laser-cutting path that will be created around the circumference of tubing from which the stent 1 is to be made.
- the pattern in FIG. 10 is broken along a longitudinal line to represent it as a flat, two-dimensional pattern.
- this two-dimensional flat pattern (representing width and length) is transformed into a two-dimensional cylindrical pattern (representing rotation and length) by the programming of the computer-controlled laser-cutting machine so that the cut pattern is arrayed continuously around the cylindrical surface of the tube.
- the resulting cut pattern produces a cylindrical or helical array of struts 5 to form the stent 1 .
- FIGS. 11 to 14 illustrate a portion of a stent 1 according to the invention with the s-shaped struts 5 oriented in the configuration shown in FIG. 3 , i.e., the straight portions are substantially aligned with the longitudinal axis of the stent 1 before expansion.
- the right end of the stent is not depicted and the left end is shown with flat-ended markers 13 extending from respective curved portions 7 .
- the narrow portions of the markers 13 have the same length and, therefore, the extreme left flat ends of the markers 13 do not align along a single planar surface orthogonal to the longitudinal axis of the stent 1 once the stent is expanded.
- FIGS. 11 to 14 illustrate a portion of a stent 1 according to the invention with the s-shaped struts 5 oriented in the configuration shown in FIG. 3 , i.e., the straight portions are substantially aligned with the longitudinal axis of the stent 1 before expansion.
- the right end of the stent
- FIGS. 11 to 14 shows the stent 1 in an expanded state after the sacrificial bridges 9 have been removed. As can be seen in each of FIGS. 11 to 14 , the bridges 8 align along a circumference of the interior cylinder defined by the stent 1 .
- the interior cylinder depicted in FIGS. 11 to 14 is only presented for illustrative purposes.
- the manufacture of the stent 1 according to the present invention are made substantially more difficult when the size of struts 5 is reduced and the number of struts 5 is increased.
- normal laser cutting processes yield a finished kerf width (after material removal processes needed to provide a stent with the desired polished finish) of approximately 25 to 40 microns. If, for example, a total of 46 struts were disposed around a circumference, then the total circumferential width of kerfs would be at least 46 ⁇ 25 microns, or 1150 microns (1.15 millimeters).
- a stent of the current configuration made by conventional manufacturing processes has at least 0.57 millimeter of incompressible circumference resulting from the kerfs at the 180-degree bends (corresponding to 0.18 millimeter of diameter reduction).
- the diameter after compression is reduced by 0.05 millimeters—a significant difference in fully collapsed diameter.
- the remaining strut widths are increased due to the fact that less metal is removed.
- the resulting strut width increases from 112 microns to 119 microns, resulting in a relative stiffness of ( 119/112) 3 , or 120%, because stiffness is proportional to the cube of width.
- the maximum embolus size that can pass through the wall of an expanded stent is determined by the size of the openings between the straight portions 6 and bending segments 7 . More precisely, the maximum embolus size is described by the largest circle that can be inscribed within the openings of a particular stent in its open configuration. It is, therefore, desirable to minimize the maximum embolus size to prevent adverse results of embolization in patients.
- the maximum size embolus that can be passed through the openings between struts has a diameter described by the largest circle that can be inscribed within the space between two adjacent struts and the vertex of a strut pair on the adjacent column of struts.
- the volume of such an embolus is proportional to the cube of the diameter. So, it can be seen that the volumetric size of the largest embolus that can pass through the stent wall becomes smaller by the third power as the strut geometry is proportionally reduced in size (assuming otherwise similar geometry of the strut openings).
- emboli can be substantially reduced by using a greater number of shorter struts; hence, clinical safety increases sharply with increases in the M-D Ratio, particularly in regions of the vasculature, such as the carotid arteries, where emboli are poorly tolerated and can have significant deleterious effects upon the patient.
- An expanded helical stent 1 according to the present invention has openings sized to prevent a body (for example an embolus or a substantially spherical body) of greater than approximately 800 microns in diameter from passing therethrough.
- the expanded helical stent 1 according to the present invention contains 46 struts of 120-micron width and 1000-micron length, for example. Such a configuration results in openings that would allow an inscribed circle 15 of 610 microns. This feature is illustrated in FIG. 15 .
- the Cordis 8 mm ⁇ 50 mm SmartStent allows a much larger inscribed circle.
- FIG. 16 shows the best-case alignment of the alternate rows of the struts in the SmartStent, allowing an inscribed circle 16 of 1080 microns.
- the volume of an embolus of 1080 microns versus that of a 610-microns embolus is 5.5 times larger.
- Another advantage of the present invention in prevention of embolization is realized in the case where the stent 1 is implanted in a bent, or non-straight, configuration.
- bending causes opening of the space or gap between adjacent turns 7 or straight portions 6 of struts on the outside of the bend.
- the present invention teaches the use of very short struts (on the order of between approximately 600 and 1200 microns in length) and, hence, a shorter helical pitch or column-to-column distance, a bending deformation to a stent results in opening of the gaps between several adjacent turns or columns of struts 4 .
- the distance by which any given gap is widened is reduced in proportion to the number of gaps involved. For example, a stent 1 with struts 5 that are half as long will have twice as many gaps affected by a bend, and the widening of each of these gaps will be reduced by a factor of two.
- stents 1 made according to the present invention have a relatively high number of features compared with stents made according to the prior art, and because there is a larger number of these features, including the straight portions 6 and the 180-degree loops 5 that provide local flexibility as well as the bridges 8 joining adjacent turns or columns of struts 4 that provide structural integrity to the overall structure, it is possible to fine-tune the flexibility and compression/expansion properties to a much finer extent than in prior-art stents with a substantially smaller number of features.
- a typical prior-art stent of the same size, for example, the Cordis 8 mm ⁇ 50 mm SmartStent has approximately 700 struts.
- an 8-millimeter diameter, 50-millimeter long stent 1 according to the present invention has approximately 1500 struts—more than a 100% increase.
- the present invention allows for much more precise use of this conventional construction technique—because the features of the stent 1 are smaller, there are more of them and, thus, the designer has a greater number of features over which to create a gradient of properties such as stiffness, radial outward force, flexural stiffness, surface area (for drug-coating application), and diameter.
- the short length of struts 5 results in a greater helix angle (or, a helical axis more closely approaching perpendicular to the longitudinal axis) for a given circumference of stent because the shorter struts 5 result in a reduced helical pitch.
- the unevenness of the distal and proximal ends of the stent is reduced because the step where the end of the helix joins the previous turn is smaller (approximately equal to the strut length).
- Such a reduced step provides for a stent 1 with a substantially square-cut end (as is typically desired by physicians) in an easier manner.
- the increased helix angle results in a stent 1 that has a reduced tendency to twist as it is expanded. It can be easily imagined that a helical stent with a very low helix angle, similar to a corkscrew, would tend to wobble and twist when released from a confining sheath. As the helix angle is increased toward perpendicular (by reducing the strut length or helical pitch), a helical stent behaves more and more like a non-helical stent constructed of joined cylindrical hoops, resulting in even, non-twisting behavior as it expands when released.
- a multiple-helix configuration As the number of starts is increased in the helix, the ends of the stent 1 begin to become more square-cut in appearance; for example, a triple-helix configuration would have three “notches” at the end where the three loose ends are joined to the adjacent turn. Because it is common to provide radiopaque markers at the ends of stents, these three notches are advantageous locations for three markers, resulting in a symmetrical, even end to the stent 1 .
- struts 5 and bridges 8 , 9 of the present invention result in the spreading of local forces and deflections brought about in use to a larger number of features, so that these local deformations are spread over a larger number of deforming elements. As a result, each element is proportionately less deformed. It is understandable that a stent with 1500 struts will more readily absorb deformation and in flexion and torsion than a stent with half as many struts, with an attendant reduction in localized loads and deformations to the vessel or other body lumen in which it is placed.
- Torsional compliance in a helical stent is determined by the ability of the helical strand of struts 5 to lengthen and shorten. Hence, a longer strand of more numerous struts 5 and their joining bending segments 7 will be better able to absorb lengthening and shortening. The result is, for stents of a given radial compressive strength and outward force, a configuration with a greater number of short struts 5 that will be more easily torsioned than one with a smaller number of longer struts 5 .
- a related result is that, because torsionally induced strains are reduced, any tendency toward fatigue failure caused by torsional motions in-vivo is also reduced.
- flexural (or bending) flexibility and fatigue resistance are also improved. Bending of a stent 1 causes adjacent turns or columns of struts 4 to be forced either toward each other (on the inside of a bend) or spread apart (on the outside of the bend). Because connecting bridges 8 join adjacent turns or columns 4 , the local deformations caused by stent bending are spread over the struts 5 and bending segments 7 (the 180-degree loops that join the ends of struts) between the connecting bridges 8 .
- the more elements (struts 5 and bending segments 7 ) that exist between the connecting bridges 8 the greater number of elements there are to absorb the deformations caused by stent bending. Also, in a configuration with shorter struts 5 , there is a greater number of turns or columns 4 acted upon by bending the stent 1 , so the total number of elements deformed by bending the stent 1 is further increased, resulting in much smaller deformations to each of the elements. As deformations are reduced and strut widths are reduced, the effective strains in the stent material are significantly reduced, resulting in much improved fatigue resistance.
- a stent 1 according to the present teachings will have over twice as much kerf length than an otherwise similar prior art stent with half as many struts around the circumference.
- kerf area the area of the cut radial faces of the stent's elements
- kerf area is the major contributor to total surface area because the area of the inner and outer surfaces is relatively smaller, due to the high aspect ratio (thickness to width) of the struts.
- the total surface area of a stent 1 made according to the present teachings is substantially larger than that of a stent made according to prior-art configurations and, thus, it provides a larger surface area on which to apply medicated coatings.
- This larger surface area allows virtually all tissue within the coverage area of the stent to be in the drug elution areas.
- the stent provides tissue coverage so that no element of wall tissue is more than 350 microns to 400 microns away from the nearest strut. Such a configuration assures a short diffusion path from a strut covered with a drug-eluting agent to any portion of the tissue.
Abstract
A method for manufacturing a helical stent includes the steps of providing a stent body with struts disposed about the circumference thereof in turns and with bridges connecting the struts in adjacent turns. The stent body is at least partially expanded and, some time during expansion, some of the bridges, in particular, sacrificial bridges, are removed. A method for implanting this stent includes loading the stent at a stent delivery system, traversing the stent at the delivery system to an implantation site, and implanting the stent at the implantation site.
Description
- This application claims the priority, under 35 U.S.C. § 119, of U.S. Provisional Patent Application No. 60/606,261 filed Sep. 1, 2004, the entire disclosure of which is hereby incorporated herein by reference in its entirety.
- n/a
- The invention lies in the field of vascular stents. In particular, the invention is in the field of helical stents for peripheral arteries, the biliary tree, and other body lumens.
- Stents have been developed for use in various lumens of the body, including the biliary tree, venous system, peripheral arteries, and coronary arteries. Stents are used to open or hold open a lumen that has been blocked (occluded) or reduced in size (stenosed) by some disease process, such as atherosclerosis or cancer. Previously developed stents for use in the biliary, venous, and arterial systems have been of two broad classes: balloon-expanded and self-expanding. In both of these classes, stents have generally been made by two different techniques: either formed from wire or machined from a hollow tube. Other manufacturing techniques have been proposed, such as vacuum or chemical deposition of material or forming a tube of machined flat material, but those “exotic” methods have not been widely commercialized.
- The vast majority of stents for use in the arterial and venous systems have been made by machining a pattern of struts and connecting elements from a metallic tubular preform (typically, by laser machining). Of these machined-tube stents, there have been two basic architectures: circumferential and helical. Circumferential configurations are based upon a series of cylindrical bands joined longitudinally by bridges to make a tubular structure. Helical configurations include a continuous helical structure (typically made of an undulating pattern of struts and end-loops) with joining structures (referred to as “bridges”) joining adjacent turns of the helix to provide mechanical integrity to the tubular structure (to prevent unwinding, kinking, and buckling).
- Fine Cell Structure of Stents
- Clinicians recommend the use of stents with relatively small openings to minimize the chances of friable material from the lumen wall penetrating into the interior of the stent where it may result in narrowing of the lumen by cellular proliferation or where it may embolize downstream, causing damage or ischemia. U.S. Pat. No. 6,537,310 to Palmaz et al. teaches that it is advantageous to cover a stent with a porous film having openings no larger than 17 microns in their smallest dimension to minimize the migration of embolic debris and plaque into the lumen of a stent. However, Palmaz teaches use of a stent that is very difficult to manufacture because of the great number of very small openings in the covering film or “web.”
- Clinicians have asked for stents with “thin, equi-spaced struts for optimal wall coverage and drug elution” (“Clinical Impact of Stent Design: Results from 10 Years Experience,” C. DiMario, TCT2003). DiMario demonstrates 15.0% restenosis versus 36.6% for stents with thin struts (50 microns, Multilink) versus thick struts (average of all stents evaluated with struts greater than or equal to 100 microns). DiMario also relates stent efficacy to “integrated cell size,” showing better results for the BX VELOCITY® stent with cells of 3.3 mm2 versus stents with larger cell sizes. DiMario reports reduced neointimal hyperplasia for smaller struts (0.8 mm thickness for closely-spaced 125-micron struts versus 1.54 mm thickness for wider-spaced 200-micron struts). Because prior art stent designs have large gaps between stent parts, drug elution about these parts does not adequately cover all of the tissue within the bounds of the stent.
- In “Clinical Impact of Stent Design: Results From Randomized Trials” (TCT 2003), A. Kastrati reports reduced residual percent-diameter stenosis after stenting (4.0% versus 5.7%) with 50-micron struts (Multi-link) versus 140-micron (Multi-link Duet).
- In his report “Era of Drug-Coated and Drug-Eluting Stents” (TCT 2002), G. Grube states that the typical open-cell configuration gives poor distribution of the drug into the arterial wall because of the large open gaps when the stent is situated in a bend of the artery.
- Number-of-Struts to Strut-Length Ratio
- U.S. Pat. No. 6,129,755 to Mathis et al. (hereinafter “Mathis”) teaches improved self-expanding stents with circumferential hoops of struts joined by oblique longitudinal bridges. Described therein is the importance of having a large number of struts per hoop (the number of struts counted by going around the circumference) and minimum strut length to minimize strains in superelastic materials and to prevent emboli from passing through the wall of the stent. Mathis defines a figure of merit that is the ratio of number of struts around the circumference to the length (in inches) of a strut, measured longitudinally. This ratio, which has the units of reciprocal inches, will be referred to herein as the M-D Ratio because the inventors were Mathis and Duerig. Mathis describes prior-art stents as having a ratio of about 200 and that their improved stent has an M-D Ratio of over 400. A representative stent produced by Cordis Corporation according to the Mathis-Duerig invention—referred to as the “SmartStent”—has 32 struts per circumference and strut lengths of approximately 0.077 inch, resulting in an M-D Ratio of approximately 416.
- The M-D Ratio is determined by number of struts divided by strut length. For a given diameter stent, assuming “maximum-metal” configuration, which is typical for self-expanding stents, the number of struts around the circumference is inversely proportional to the strut width. Thus, the M-D Ratio is inversely proportional to the product of strut width and length.
- It is accordingly an object of the invention to provide a helical stent and a method for manufacturing the stent that overcome the hereinafore-mentioned disadvantages of the heretofore-known devices of this general type and that improves helical machined-tube stents, whether balloon-expanded or self-expanding.
- The self-expended stent of the present invention is suitable for use in peripheral arteries, the biliary tree, and other body lumens. In particular, it will be most advantageous for use in arteries where flexure is an important factor, such as iliac arteries and carotid arteries. It is not traditional for cardiologists to use self-expanding stents in coronary arteries or coronary bypass grafts. Nonetheless, the present invention is especially suitable for the diffuse disease often encountered in these locations. Also, because of the high total surface area of the present configuration, the stent is particularly suitable for the application of drug-eluting coatings intended to reduce restenosis or for other therapies. Specifically, the stent according to the present invention allows virtually all tissue within the coverage area of the stent to be in the elution areas. In particular, the stent provides tissue coverage so that no element of wall tissue is more than 350 microns to 400 microns away from the nearest strut. Such a configuration assures a short diffusion path from a strut covered with a drug-eluting agent to any portion of the tissue.
- With the foregoing and other objects in view, there is provided, in accordance with the invention, a method for manufacturing a helical stent, includes the steps of providing a stent body with a circumference, with struts disposed about the circumference in turns, and with bridges connecting the struts in adjacent ones of the turns, and, after at least partially expanding the stent body, removing some of the bridges.
- With the objects of the invention in view, there is also provided a method for implanting a stent, including the steps of providing the helical stent, loading the stent at a stent delivery system, traversing the stent at the delivery system to an implantation site, and implanting the stent at the implantation site.
- In accordance with another mode of the invention, the struts are formed in a helix.
- In accordance with a further mode of the invention, the removing step is carried out by polishing and cleaning the stent body in processes selected from at least one of the group consisting of chemical, mechanical, and electrochemical. The processes can include abrasive blasting, glass-bead honing, chemical etching, mechanical polishing, electrochemical polishing, grinding, shearing, and cutting.
- In accordance with yet another mode of the invention, after carrying out the removing step, the stent body is radially compressed.
- In accordance with an added mode of the invention, after carrying out the removing step, the stent body can be crimped onto a balloon catheter. Thereafter, the stent body is retained in the crimped state for delivery to an implantation site.
- In accordance with an additional mode of the invention, after carrying out the removing step, the stent body is chilled and radially compressed. Thereafter, the stent body is retained in a compressed state for delivery to an implantation site.
- In accordance with yet a further mode of the invention, the stent body is provided with connecting bridges and sacrificial bridges each connecting the struts in adjacent ones of the turns.
- In accordance with yet an added mode of the invention, all of the sacrificial bridges can be partially removed. Substantially all of the sacrificial bridges can be removed. Only connecting bridges can be present at the stent body after expansion.
- In accordance with yet an additional mode of the invention, the stent body can have a diameter of between approximately 4 mm and approximately 12 mm and/or a length of between approximately 10 mm and approximately 250 mm. The stent body can have s-shaped struts disposed helically about the circumference along helical turns, the struts having straight portions and curved portions connecting at least some of respectively adjacent ones of the straight portions. The stent body can have a finished kerf width of less than 25 microns, in particular, a width of approximately 18 microns.
- In accordance with again another mode of the invention, the stent body can have a pre-cut tubing diameter of approximately 2 millimeters, a post-cut number of struts per turn equal to 46, a finished kerf width of approximately 18 microns, and a post-cut strut width of 119 microns.
- In accordance with again a further mode of the invention, the bridges can have an initial curvature shape and expansion of the stent body is controlled to substantially retain all of the initial curvature shape of the bridges.
- In accordance with a concomitant mode of the invention, implantation of the stent is in a blood vessel. The stent is expanded at the implantation site. If the stent is a balloon-expanding stent, then the stent is expanded with a balloon of a stent delivery system. If the stent is a self-expanding stent, then the stent is allowed to self-expand at the implantation site.
- The present invention relies on a helical configuration with much shorter struts and significantly higher number of struts around the circumference than the prior art. Indeed, helical stent configurations according to the present invention are not limited to even-integral numbers of struts—as are “hoop” configurations taught by Mathis. In fact, odd-integral numbers of struts around the circumferential or even non-integral numbers of struts around the circumference are possible in the helical configuration of the present invention because there is no requirement for the struts to rejoin themselves to make complete hoops. In other words, a helical stent could have 31.567 struts per revolution, or any other arbitrary number. Mathis teaches that increasing the M-D ratio increases the rigidity of a stent, yet the rigidity of two comparative stents bears this relationship only if the stents being compared are expanded to comparable opening angles between the struts. In fact, with commercially available stent product lines produced to the M-D configuration, stents of different diameters frequently have the same number of struts. Even so, such a configuration family has smaller opening angles in smaller sizes than in larger sizes; this is because similar stent preforms are used to make a range of final stent sizes. The smaller stents in a product family sharing the same preform configuration (including the number of struts) have smaller opening angles, of course, resulting in lower chronic outward force (COF) and lower radial resistive force (RRF) to collapse, because the effective bending-lever length is longer in struts with lower opening angles. Mathis teaches M-D Ratios of over 400 and numbers of struts up to 32 or more but does not teach or suggest ratios of near or over eight-hundred (800), let alone over one thousand (1000). Mathis, specifically, does not mention what effects a much larger number of struts would have, and does not imply implementation of significantly shorter struts.
- In the present invention, an exemplary configuration for an 8 mm diameter stent incorporates 46 struts around the helical circumference and the struts have a length of approximately 0.99 mm (0.039 inches). The M-D Ratio for this exemplary configuration according to the present invention is, therefore, 1180—nearly three times the ratios taught in the prior art. Stents according to the present invention have new and unexpected properties, even though they require greater attention to opening angles (and, hence, have a more limited useful size range for a given configuration).
- In comparison with prior art stents having cells of 3.3 mm2, the present invention gives an integrated cell size of 1.6 mm2 per cell unit in an 8 mm diameter stent. In a configuration with bridges every three cell units, the total integrated cell size would be 4.8 mm2, which is proportionately smaller than that of the
BX VELOCITY® 3 mm stent. - Specifically, configurations according to the present invention have much smaller openings when expanded and, particularly, when the expanded stent is flexed in bending. The substantially smaller openings result in greatly improved resistance to the passage of emboli through the stent wall.
- Another characteristic of stents according to the present invention is a greatly increased flexibility and resistance to buckling in bending or torsion. Stents according to the present invention also have improved fatigue life in real-life applications, resulting from a large number of struts and bending segments to absorb irregular, localized deformations caused by the anatomy—as opposed to such local deformations being placed on a small number of struts and bending segments, which results in over-straining some of these elements.
- Stent configurations optimized for a particular expanded diameter will have struts as wide as possible, consistent with the maximum allowable strain during storage and compression. The result of such a criterion is that stent configurations according to the present invention, with a greater number of struts of shorter length and narrower width than prior art configurations, will allow greater bending deflections, resulting in greater possible opening angles. Constructing an expanded stent with greater allowed opening angles also results in a relatively shorter projected lever-arm length acting on the struts and bending segments when the stent is expanded in the anatomy. These shorter lever arms result in higher outward forces applied to the vessel walls when the stent is expanded.
- It should be noted that the present invention results in configurations that are optimized for a small range of expanded sizes, creating the need to have individualized configurations for each expanded size of stent. This approach deviates from the prior art and results in higher configuration and validation costs, but results in stents with significantly improved flexural and fatigue properties while, at the same time, providing optimized radial outward forces and collapse resistance for each size.
- Another characteristic of stents made according to this invention is the increased difficulty of collapsing the stent when preparing it for insertion into a delivery catheter. The struts of stents made according to the present invention are proportionately narrower and, hence, less stiff in bending (in proportion to the cube of the width of the struts) when compared to prior art stent designs. This decrement in stiffness may be offset by increasing the opening angle of the stent, as described elsewhere herein, but the reduced stiffness of the struts (and also the increased opening angles) results in a tendency for portions of the helix to buckle when subjected to the stresses and strains required to fully collapse the stent prior to insertion into its delivery system. The result of this buckling is that a series of struts and loops forming a portion of the helical winding will resist collapsing uniformly along the helical axis, but rather buckle away from the helical axis (usually remaining in the plane of the cylindrical surface of the stent). When a portion of the helix buckles, the struts of that turn may begin to interfere or interdigitate with the struts of an adjacent helical turn. Thus, stents made according to the present invention are more difficult to compress into their delivery system.
- This tendency for a series of struts and loops to buckle away from the helical axis is aggravated when the struts are very narrow, when the opening angles are higher, and when there is a long series of struts between the connecting bridges. The presence of the connecting bridges that join adjacent turns of the stent stabilizes the stent during compression; this stability is greater when there are only a few struts between bridges, and the stability is reduced when there is a large number of struts between bridges. For example, stents made with series of seven or nine struts between bridges have a high tendency toward buckling when compressed; stents made with five struts between bridges have an intermediate tendency toward buckling when compressed; and, stents with only three struts between bridges have a low tendency toward buckling when compressed. It should be noted that this tendency toward buckling does not adversely affect the characteristics of the stent when expanded in the body, because the compressive strains experienced in the body are insufficient to cause the buckling seen during compression into the delivery system. However, it has been found that stents with very low numbers of struts between bridges (e.g., one or three), though they are very easy to fully compress, do not have flexibility as great as that of stents with larger numbers of struts between bridges (e.g., seven or nine). As a result, it has been found that there is a tradeoff between design choices which create a stent that is easy to compress versus choices which make the stent flexible. It has been found that stents made according to this invention, configured with an M-D ratio in the range of 1000, have the most favorable balance of flexibility and buckling during compression when the number of struts between bridges is in the range of three to five.
- Other features that are considered as characteristic for the invention are set forth in the appended claims.
- Although the invention is illustrated and described herein as embodied in a helical stent and a method for manufacturing the stent, it is, nevertheless, not intended to be limited to the details shown because various modifications and structural changes may be made therein without departing from the spirit of the invention and within the scope and range of equivalents of the claims.
- The construction and method of operation of the invention, however, together with additional objects and advantages thereof, will be best understood from the following description of specific embodiments when read in connection with the accompanying drawings.
-
FIG. 1 is a fragmentary, enlarged partially cross-sectional and partially plan view of a stent delivery system configured to implant a stent according to the invention in a vessel; -
FIG. 2 is a fragmentary, enlarged plan view of the stent ofFIG. 1 expanded and implanted in the vessel; -
FIG. 3 is a fragmentary, enlarged plan view of a portion of a first embodiment of the stent ofFIG. 1 ; -
FIG. 4 is a fragmentary, enlarged plan view of a portion of a second embodiment of the stent ofFIG. 1 ; -
FIG. 5 is a fragmentary, enlarged plan view of a portion of the second embodiment of the stent ofFIG. 4 with circular markers; -
FIG. 6 is a fragmentary, enlarged plan view of a portion of the first embodiment of the stent ofFIG. 3 with flat-ended markers; -
FIG. 7 is a fragmentary, enlarged plan view of a further enlarged portion of the first embodiment of the stent ofFIG. 3 with some sacrificial bridges removed; -
FIG. 8 is a fragmentary, side elevational view of a portion of an expanded stent according to the invention with a protruding bridge; -
FIG. 9 is a fragmentary, enlarged plan view of a further enlarged portion of the first embodiment of the stent ofFIG. 7 with the sacrificial bridges having break points; -
FIG. 10 is a plan view of a flat cut pattern representing the laser-cutting path to be created around a circumference of tubing from which the stent according to the invention is to be created; -
FIG. 11 is a fragmentary, enlarged, perspective view from the side of a stent according to the invention; -
FIG. 12 is a fragmentary, further enlarged, perspective view of a portion of the stent ofFIG. 11 ; -
FIG. 13 is a fragmentary, enlarged, perspective view from an end of the stent ofFIG. 11 ; -
FIG. 14 is a fragmentary, further enlarged, perspective view of a portion of the stent ofFIG. 13 ; -
FIG. 15 is a fragmentary, enlarged plan view of a portion of an expanded stent according to the invention illustrating a largest embolism area; and -
FIG. 16 is a fragmentary, enlarged plan view of a portion of a prior art stent illustrating a largest embolism area. - Referring now to the figures of the drawings in detail and first, particularly to
FIG. 1 thereof, there is shown is ahelical stent 1 according to the present invention fitted on adelivery catheter 20 of anexemplary delivery system 10. Thehelical stent 1 is about to be implanted in avessel 30. Thehelical stent 1 is in its unexpanded state and loaded into/onto thedelivery system 10 that has traveled to an implantation site.FIG. 2 illustrates thehelical stent 1 implanted in thevessel 30 after being expanded, whether by a balloon of thecatheter 20 or by self-expansion due to a shape memory of the material of thestent 1. - The
helical stent 1 has proximal 2 and distal 3 ends—defined by a blood flow direction A. The helix of thestent 1 can be a single coil with one start at the proximal end that winds all the way to the distal end. Such a configuration is possible with the present invention because thehelical stent 1 has very short struts, which will be explained in further detail below. Another configuration alternative usable with short struts is a multiple-helix configuration (shown in FIG. 2), where more than one helixed start is present, for example, a double-lead, a triple-lead, and so on. With an exemplary 8 mm size of the helical stent according to the present invention, up to 4 leads are practical. -
FIGS. 3 and 4 show enlarged views of a portion of the body of thehelical stent 1 of the present invention. Eachturn 4 of the helix is formed, in a preferred embodiment, by a continuous repetition of s-shapedstruts 5 throughout the length of the helix. Thestruts 5 havestraight portions 6 andcurved portions 7 connecting respectively adjacentstraight portions 6. Connectingbridges 8 have a width substantially similar to a width of the straight andcurved portions adjacent turns 4 of the helix. Also connecting adjacent turns of the helix aresacrificial bridges 9, which have a width smaller than a width of the straight andcurved portions bridges -
Stents 1 may be made according to the present invention withstruts 5 that are aligned with thelongitudinal axis 10 of thestent 1, as shown inFIG. 3 , or thestruts 5 may be aligned perpendicular to thehelical direction 11, as shown inFIG. 4 . There are advantages and differences to both configurations. The longitudinally alignedstraight portions 6 of thestruts 5 produce astent 1 that requires lower force to deploy from a confining sleeve because there are no oblique, twisting, knife-edges to cut into or grip the sleeve. One characteristic of this embodiment, is that thestruts 6 are not of equal length (there is an equal number of short and long struts) and, therefore, it is not possible to fully balance the flexibility of these struts to fully utilize the properties of the material used to build thestent 1. In comparison, the configuration shown inFIG. 4 with helically alignedstraight portions 6 of thestruts 5 has the advantage of equal strut lengths. This configuration, in comparison, has a higher friction when thestent 1 is engaged inside a deployment system. - Other advantages and differences exist for these two configurations, including ease of manufacture, ease of inspection, and stability during expansion or deployment of the longitudinal and helically aligned strut configurations. But, either may be used to practice the teachings of the present invention.
- Lollipop Crown and Retention Levers
- It is customary to provide radiopaque markers on stents so that they can be easily visualized by using x-rays for assisting their placement and deployment. The present invention provides a convenient area at which to locate these markers, specifically, beyond the ends of the helical pattern of struts. If the
markers 12 are paddle-shaped (that is, having a substantially disk-like enlarged portion with a narrow extension that joins it to the structure of the stent), they may be attached to the ends of the 180-degree bending segments 7 (or to other locations on the bendingsegments 7 or straight portions 6). It is advantageous to dispose the markers so that a paddle with a short extension is located near the end of the helix (the extreme end of the helical pattern) and paddles on longer connectors are located at other locations around the circumference. In such a configuration, the extreme ends of the paddles are even, providing a relatively planar end to thestent 1. However, themarker portions 12 need not be paddle-shaped. They can merely be rod-shaped to extend away from either or both of the distal andproximal ends stent 1. These rods can be expanded for better seating in the vessel and, even with a smaller surface area as compared to the paddle-shaped markers, can still provide sufficient area for receiving indicators that allow for better imaging. - The flat end provided by the paddle-shaped
markers 12 ofFIG. 6 , for example, facilitates pushing thestent 1 out of a deployment device (although a shaped pusher that conforms to the helical end of the stent could be used but is harder to manufacture and align). During deployment of a self-expanding stent, a pusher component of a delivery catheter exerts a (distally-directed) counter-force onto the proximal end of the stent while a covering sleeve is retracted from its position over the stent. As the covering sleeve is retracted relative to the stent and the pusher, the distal end of the stent is exposed and, therefore, expands to contact the interior of the vessel. Thus, it is important for the pusher to be able to apply evenly the distally directed force onto the proximal end of the stent during deployment. Also, for most medical indications, physicians prefer stents with flat ends substantially perpendicular to the longitudinal axis of the device so that there is an even transformation from the end of the stent to the unsupported (unstented) portion of the vessel wall. - The paddle shaped
markers 12 described above can be spaced from the helical end of the stent by narrow connectors as shown inFIGS. 5 and 6 , or by full-width connectors (i.e., markers that are of uniform width from their ends to the point where they join the struts or loops of the stent), or by directly connecting them to the other elements of the stent.FIG. 5 , for example, illustrates three paddle-shapedmarkers 12 attached by narrow connectors to the helical end of a portion of astent 1. - While the disk-like enlarged portions of paddle-shaped
markers 12 can be rounded, it is preferable for the extreme outer ends to be relatively straight. As such, the paddle-shapedmarkers 12 may be provided with non-circular ends 13 to facilitate engagement of the pushing device of the deployment catheter with which the stent is implanted. For example,FIG. 6 shows flat-ended paddle-shapedmarkers 12 that maximize contact between the paddles and the pushing device. - In addition, the paddle-shaped
markers 12 may be used to help anchor thestent 1 during and after deployment. Specifically, the paddles may be radially expanded further than thestruts stent 1 once expanded. - While the present drawings show paddle-shaped markers without separate radiopaque inserts, it should be noted that pieces of radiopaque materials, such as tungsten, tantalum, molybdenum, platinum, or gold, might be inserted into the markers to enhance their visibility under x-rays. For example, inserted cylinders of tantalum 0.50 millimeters in diameter and having a thickness equal to or less than that of the marker paddles, may be pressed, glued, riveted, threaded, or otherwise attached into holes or depressions formed in the paddles.
- Circumferential Bridges and Fixation Structures
- According to the present invention, there is an array of connecting
bridges 8 that connect adjacent turns or columns ofstruts 4 to provide the desirable overall stent flexibility as well as structural integrity. It is advantageous to form thesebridges 8 in a substantially circumferential direction, as shown inFIG. 7 . Two advantageous characteristics emerge by so forming the connecting bridges 8. First, the vertical (circumferential) offset caused by thebridges 8 ensures that, after expansion, the adjacent 180-degree bending segments (the vertices of the expanded strut pairs) are offset from one another and, thus, will interdigitate, allowing thestent 1 to bend easily. Second, thesecircumferential bridges 8 are curved sharply in the plane perpendicular to theaxis 10 of thestent 1, which curvature results from thestent 1 being formed from small-diameter tubing. By careful control of the expansion process, it is possible to expand thestent 1 while retaining substantially all of the curvature of thesebridges 8. In the resulting expandedstent 1, thesebridges 8, then, extend radially away from the cylindrical surface of thestent 1 and present edges perpendicular to theaxis 10 of thestent 1. Thus, during and after implantation, these features engage the vessel orbody lumen wall 30, preventing migration of thestent 1. The enlargement of abridge 8 inFIG. 8 illustrates how these structures protrude beyond the wall of astent 1 in this manner. - Customarily, radiopaque materials such as gold, tantalum, zirconium oxide, barium and bismuth salts, hafnium, molybdenum, etc., are attached to stents to enable visualization by x-rays. The present invention is suitable for incorporating such markers, especially at the location of the
paddles - In addition to the prior-art use of radiopaque markers, it is possible to use other types of fiducial markers to enable placement, deployment, and subsequent location and diagnosis of the
stent 1. Specifically, other non-illustrated markers can be made that are easily imaged by ultrasound, such as abraded surfaces, holes, voids, porous materials and coatings, hollow balloons, and layered materials of different sonic properties, to name a few. For example, a hole 0.50 millimeters in diameter may be filled with a composite consisting of glass microballoons and tungsten powder suspended in an epoxy matrix. Such a composite marker would be highly visible under ultrasound imaging as well as x-ray imaging. Additionally, markers having varying textures have improved anchoring characteristics. - Magnetic resonance imaging may be enhanced by inclusion of paramagnetic, diamagnetic, and ferromagnetic materials that locally change the magnetic-field-producing spin-energy transitions in odd-number nuclei such as hydrogen, carbon-13, fluorine-19, and other nuclides known to those skilled in the art of magnetic resonance imaging. Specifically, small pieces of gadolinium or gadolinium salts (paramagnetic) provide visible changes to the image formed by hydrogen nuclei in their vicinity, thus, such materials can be incorporated into fiducial markers. Nano-scale ferromagnetic materials, such as hematite or other oxides, can also provide useful MRI artifacts without troublesome image distortion.
- Magnetically active elements, salts, and compounds can be incorporated individually or in combination with other marker materials, such as radiopaque materials or ultrasound-visible structures or materials, to make multi-mode markers. Composite markers may contain materials with magnetic properties suitable to present fiducial marks on images made by magnetic resonance imaging (MRI) as well as other imaging modalities. Examples include combinations of radiopaque materials (such as, tungsten powder, zirconium oxide, bismuth subcarbonate, and gold powder), magnetically active materials such as diamagnetic or ferromagnetic materials (including gadolinium foil and powder, gadolinium salts, nanocrystalline iron oxide, and iron powder, for example), and ultrasonically visible material such as glass or ceramic microballoons.
- Manufacturing
- The standard method for manufacturing machined tubular metal stents is to begin with a small-diameter metallic tube, typically, of stainless steel, platinum alloy, or chromium-cobalt alloy for balloon-expanded stents and of a nickel-titanium alloy for self-expanding stents. This tubing is mounted in a laser machining system that rotates the part around a stationary axis so that the focal point of a laser beam impinges upon the surface of the tube. When laser power is applied along with a coaxial jet of gas (either air, oxygen, or an inert gas such as argon), the material is perforated by the laser energy (and possibly assisted by chemical reaction with air or oxygen). The tubing is moved under the laser beam in at least two axes, rotational and longitudinal, so that a continuous cut (or kerf) is made while the laser energy is applied. The laser beam is switched on and off under computer control in coordination with the longitudinal and rotational motions so that a discontinuous pattern of cuts is applied to the tubing.
- Following the laser-cutting operation, excessive material is removed from the interior and exterior surfaces of the tubing, and the tubing is further processed to produce either a balloon-expandable or a self-expanding stent. In the case of a balloon-expandable stent, the laser-cut tubing preform is polished and cleaned using a combination of chemical, mechanical, and electrochemical measures to produce a finished stent that is, then, for example, crimped onto a balloon catheter. In the case of a self-expanding stent, the laser-cut tubing is expanded by forcing it onto a succession of larger and larger mandrels. At each step of expansion, the tubing is subjected to an appropriate heat-treating step to thermally set the expanded step. For example, nickel-titanium tubing may be heat treated at 480 degrees Celsius (480° C./896° F.) for thirty seconds while expanded on a mandrel to set that stage of expansion. Typically, two to six expansion stages are necessary to fully expand a nickel-titanium self-expanding stent. After expansion, the stent is finished by a combination of chemical, mechanical, and electrochemical polishing to produce a smooth, biocompatible surface suitable for implantation. The finished stent is, then, chilled (to transform it to the soft and deformable martensitic condition) and compressed radially to a size small enough to be placed into catheter of the stent delivery system.
- The Importance of Uniform Expansion During Manufacturing
- One manufacturing problem that must be overcome with self-expanding stents having the fine structures as described in the present invention is uneven opening occurring during thermo-mechanical expansion of the as-cut tubing to the final, expanded stent. The standard manufacturing process involves stretching the laser-cut stent over progressively larger tapered-end cylindrical mandrels and heat-treating the material at several stages while supported by these mandrels. The stent can be expanded by stretching it onto the successive expansion mandrels either at a low temperature (in the soft, martensitic condition) or at ambient temperature (in the springy, austenitic condition). Once expanded onto a mandrel, the stent is exposed for a short period (several seconds to a few minutes) of high temperature, typically in the 450 to 500 Celsius range, to “shape-set” or anneal the stent at that level of expansion.
- While the expansion process has been well understood by stent manufacturers in the past, it is problematic because great care must be exercised to make sure that no portion of the stent is over-strained (over-stretching or over-bending) during the stages of expansion. Over-straining can damage permanently the superelastic material of which the stent is formed (typically a nickel-titanium superelastic alloy), resulting in hidden defects within the material that might cause immediate fracture or, worse, fatigue failure after the stent has been implanted. Therefore, manufacturers typically expand stents in several fractional steps, and may employ elaborate measures, either by human skill or tooling, to prevent any portion of the stent from being over-strained. Over-straining is most commonly seen as a pair of struts having an unusually large opening angle at their vertex relative to the angle of other strut pairs in the vicinity. This condition must be controlled and identified by in-process inspection because it may be hidden by later expansion steps and because it is an inherently unstable condition. That is, during a given expansion step, once a pair of struts begins to open excessively, that vertex becomes weakened, and the opening strains tend to be further concentrated on that particular pair of struts, so that it becomes progressively more over-strained.
- Sacrificial Bridges
- The present invention provides a process for preventing this local over-straining. In the present invention, as compared to the original number of
bridges few bridges 8 exist in the finished stent, which remainingbridges 8 provide the desired flexibility and resistance to fatigue. In the as-cut condition and during the steps of expansion, additionalsacrificial bridges 9 connect the bending segments joining strut pairs in adjacent turns or columns. Thus, when thestent 1 of the present invention is being expanded, it has greatly improved robustness, and each pair of struts is connected at the maximum number of points to adjacent parts of the expanding stent. What is referred to herein assacrificial bridges 9 provides these additional connections and causes the expansion strains to be much more evenly shared by all the elements of the stent, which sharing results in a significant increase in the evenness of strains during expansion. The result is an expanded stent with vertex opening angles that have much less variation. - It is true that the
sacrificial bridges 9 substantially reduce the flexural (bending) flexibility of thestent 1. Thus, they must be removed prior to finishing thestent 1. Thesesacrificial bridges 9 may be removed at any stage after expansion, but, preferably, they are removed immediately after the final expansion heat-treating step, prior to any material-removal or polishing steps, so that any burrs left by removal will be reduced or eliminated during the polishing steps. Alternatively, thesacrificial bridges 9 may be removed after some of the expansion stages, but prior to one or more final expansion stage because it has been found that, once thestent 1 has been partially expanded in a very even manner, subsequent expansion steps do not generally introduce unevenness among the opening angles. In any case, it is only necessary to remove the extra,sacrificial bridges 9 at some point prior to implantation so that thefinished stent 1 has the desired flexibility in its final, implanted form. - Bridge Removal Processes
- To facilitate removal of the
sacrificial bridges 9, special features can be engineered into the as-cut structure to provide prescribed locations for cutting or breaking thesacrificial bridges 9. These features are illustrated inFIG. 9 as, for example,notches 14 formed at one or both of the ends of thesacrificial bridges 9 connected to the struts ofadjacent turns 4. While providingnotches 14 is only one example to form the cutting/breaking location, alternative exemplary methods of removing sacrificial bridges include chemical etching, abrasive blasting, grinding, electrochemical etching or polishing, shearing, or laser cutting. - Final Burr Removal Processes
- Customarily, stents are finished by a combination of abrasive blasting, glass-bead honing, chemical etching, mechanical polishing, and electrochemical polishing. All of these processes assist removal of any remaining burr left by the removal of the
sacrificial bridges 9. In addition, other measures, such as grinding, shearing, mechanical polishing, and cutting may be used to locally smooth and remove burrs left by thesacrificial bridges 9. -
FIG. 10 illustrates a flat cut pattern representing the laser-cutting path that will be created around the circumference of tubing from which thestent 1 is to be made. For clarity, the pattern inFIG. 10 is broken along a longitudinal line to represent it as a flat, two-dimensional pattern. In practice, however, this two-dimensional flat pattern (representing width and length) is transformed into a two-dimensional cylindrical pattern (representing rotation and length) by the programming of the computer-controlled laser-cutting machine so that the cut pattern is arrayed continuously around the cylindrical surface of the tube. The resulting cut pattern produces a cylindrical or helical array ofstruts 5 to form thestent 1. - FIGS. 11 to 14 illustrate a portion of a
stent 1 according to the invention with the s-shapedstruts 5 oriented in the configuration shown inFIG. 3 , i.e., the straight portions are substantially aligned with the longitudinal axis of thestent 1 before expansion. In FIGS. 11 to 14, the right end of the stent is not depicted and the left end is shown with flat-endedmarkers 13 extending from respectivecurved portions 7. The narrow portions of themarkers 13 have the same length and, therefore, the extreme left flat ends of themarkers 13 do not align along a single planar surface orthogonal to the longitudinal axis of thestent 1 once the stent is expanded. The embodiment of FIGS. 11 to 14 shows thestent 1 in an expanded state after thesacrificial bridges 9 have been removed. As can be seen in each of FIGS. 11 to 14, thebridges 8 align along a circumference of the interior cylinder defined by thestent 1. The interior cylinder depicted in FIGS. 11 to 14 is only presented for illustrative purposes. - Using Very Narrow Kerfs in Stents with High Strut Count
- It has been discovered that the manufacture of the
stent 1 according to the present invention, in particular, the laser cutting and expansion steps, are made substantially more difficult when the size ofstruts 5 is reduced and the number ofstruts 5 is increased. For example, it has been found that normal laser cutting processes yield a finished kerf width (after material removal processes needed to provide a stent with the desired polished finish) of approximately 25 to 40 microns. If, for example, a total of 46 struts were disposed around a circumference, then the total circumferential width of kerfs would be at least 46×25 microns, or 1150 microns (1.15 millimeters). Of this kerf space, half is not collapsible during compression of the stent, because half of the kerfs are at the inside of the 180-degree bends that join the ends of the struts. Hence, a stent of the current configuration made by conventional manufacturing processes has at least 0.57 millimeter of incompressible circumference resulting from the kerfs at the 180-degree bends (corresponding to 0.18 millimeter of diameter reduction). However, by reducing the total kerf from 25 microns to 18 microns according to the present invention, the diameter after compression is reduced by 0.05 millimeters—a significant difference in fully collapsed diameter. Moreover, by reducing the kerf from the conventional 25 microns to 18 microns, a further advantage is obtained—the remaining strut widths are increased due to the fact that less metal is removed. In the present example, reducing total kerf loss from 25 microns to 18 microns, assuming a pre-cut tubing diameter of 2 millimeters and 46 struts, the resulting strut width increases from 112 microns to 119 microns, resulting in a relative stiffness of ( 119/112)3, or 120%, because stiffness is proportional to the cube of width. - The use of these very narrow kerfs is particularly advantageous to the present invention because of the large number of
struts 5 in the configuration—strut counts from 36 to 50, as compared with traditional stents customary strut count, typically in the range of 24 to 32. - Cell Opening Size
- The maximum embolus size that can pass through the wall of an expanded stent is determined by the size of the openings between the
straight portions 6 andbending segments 7. More precisely, the maximum embolus size is described by the largest circle that can be inscribed within the openings of a particular stent in its open configuration. It is, therefore, desirable to minimize the maximum embolus size to prevent adverse results of embolization in patients. - Referring to
FIG. 6 of U.S. Pat. No. 6,129,755 to Mathis et al. (which is hereby incorporated by reference in its entirety), it can be seen that the maximum size embolus that can be passed through the openings between struts has a diameter described by the largest circle that can be inscribed within the space between two adjacent struts and the vertex of a strut pair on the adjacent column of struts. The volume of such an embolus is proportional to the cube of the diameter. So, it can be seen that the volumetric size of the largest embolus that can pass through the stent wall becomes smaller by the third power as the strut geometry is proportionally reduced in size (assuming otherwise similar geometry of the strut openings). From this analysis, it can be appreciated that the clinical effect of emboli can be substantially reduced by using a greater number of shorter struts; hence, clinical safety increases sharply with increases in the M-D Ratio, particularly in regions of the vasculature, such as the carotid arteries, where emboli are poorly tolerated and can have significant deleterious effects upon the patient. - An expanded
helical stent 1 according to the present invention has openings sized to prevent a body (for example an embolus or a substantially spherical body) of greater than approximately 800 microns in diameter from passing therethrough. In a preferred configuration, the expandedhelical stent 1 according to the present invention contains 46 struts of 120-micron width and 1000-micron length, for example. Such a configuration results in openings that would allow an inscribedcircle 15 of 610 microns. This feature is illustrated inFIG. 15 . By comparison, theCordis 8 mm×50 mm SmartStent allows a much larger inscribed circle.FIG. 16 shows the best-case alignment of the alternate rows of the struts in the SmartStent, allowing an inscribedcircle 16 of 1080 microns. The volume of an embolus of 1080 microns versus that of a 610-microns embolus is 5.5 times larger. Thus, it can be seen that the present invention allows a much-increased ability to prevent the passage of clinically significant emboli through its pores. - Another advantage of the present invention in prevention of embolization is realized in the case where the
stent 1 is implanted in a bent, or non-straight, configuration. In prior-art stents, bending causes opening of the space or gap betweenadjacent turns 7 orstraight portions 6 of struts on the outside of the bend. Because the present invention teaches the use of very short struts (on the order of between approximately 600 and 1200 microns in length) and, hence, a shorter helical pitch or column-to-column distance, a bending deformation to a stent results in opening of the gaps between several adjacent turns or columns ofstruts 4. Thus, the distance by which any given gap is widened is reduced in proportion to the number of gaps involved. For example, astent 1 withstruts 5 that are half as long will have twice as many gaps affected by a bend, and the widening of each of these gaps will be reduced by a factor of two. - Smooth Stiffness Gradient from High Bridge Frequency
- Because
stents 1 made according to the present invention have a relatively high number of features compared with stents made according to the prior art, and because there is a larger number of these features, including thestraight portions 6 and the 180-degree loops 5 that provide local flexibility as well as thebridges 8 joining adjacent turns or columns ofstruts 4 that provide structural integrity to the overall structure, it is possible to fine-tune the flexibility and compression/expansion properties to a much finer extent than in prior-art stents with a substantially smaller number of features. A typical prior-art stent of the same size, for example, theCordis 8 mm×50 mm SmartStent, has approximately 700 struts. In comparison, for example, an 8-millimeter diameter, 50-millimeterlong stent 1 according to the present invention has approximately 1500 struts—more than a 100% increase. - It is possible to adjust the size and width of
struts 5 along the length of thestent 1. However, the present invention allows for much more precise use of this conventional construction technique—because the features of thestent 1 are smaller, there are more of them and, thus, the designer has a greater number of features over which to create a gradient of properties such as stiffness, radial outward force, flexural stiffness, surface area (for drug-coating application), and diameter. - In a similar manner, because of the large number of connecting
bridges stent 1. Among the properties affected by bridge frequency and location are flexural stiffness and torsional stiffness. Therefore, it is possible to construct a stent with greater torsional rigidity in the central portion than in the ends, or vice-versa. Similarly, it is possible to provide thestent 1 with more bending flexibility at its ends (and, hence, lower stresses applied to the vessel walls) than in the central segment by placing fewer connectingbridges stent 1 than in the middle. (Of course, the opposite possibility also exists, providing astent 1 with stiff ends and a more flexible central segment, suitable for use in an area of the body where flexion takes place.) - Short-Pitch Helix
- Also, it can be seen that the short length of
struts 5 results in a greater helix angle (or, a helical axis more closely approaching perpendicular to the longitudinal axis) for a given circumference of stent because theshorter struts 5 result in a reduced helical pitch. There are several advantages to such an increase in helix angle. First, the unevenness of the distal and proximal ends of the stent is reduced because the step where the end of the helix joins the previous turn is smaller (approximately equal to the strut length). Such a reduced step provides for astent 1 with a substantially square-cut end (as is typically desired by physicians) in an easier manner. - Second, the increased helix angle results in a
stent 1 that has a reduced tendency to twist as it is expanded. It can be easily imagined that a helical stent with a very low helix angle, similar to a corkscrew, would tend to wobble and twist when released from a confining sheath. As the helix angle is increased toward perpendicular (by reducing the strut length or helical pitch), a helical stent behaves more and more like a non-helical stent constructed of joined cylindrical hoops, resulting in even, non-twisting behavior as it expands when released. Even though some of the resulting properties of a stent with a high helix angle approach those that are advantageous in a non-helical stent (such as a nearly square end and resistance to twisting during expansion), the advantageous properties intrinsic to a helical stent are maintained, such as greater design freedom, lack of distinct rigid and flexible zones along the length of the stent, and more-uniform distribution of applied stresses and strains. - As set forth above, another configuration alternative that becomes practicable with the very
short struts 5 of the present invention is the employment of a multiple-helix configuration. As the number of starts is increased in the helix, the ends of thestent 1 begin to become more square-cut in appearance; for example, a triple-helix configuration would have three “notches” at the end where the three loose ends are joined to the adjacent turn. Because it is common to provide radiopaque markers at the ends of stents, these three notches are advantageous locations for three markers, resulting in a symmetrical, even end to thestent 1. - Torsional Compliance and Torsional Fatigue Resistance
- The greater number of
struts 5 andbridges - Torsional compliance in a helical stent is determined by the ability of the helical strand of
struts 5 to lengthen and shorten. Hence, a longer strand of morenumerous struts 5 and their joiningbending segments 7 will be better able to absorb lengthening and shortening. The result is, for stents of a given radial compressive strength and outward force, a configuration with a greater number ofshort struts 5 that will be more easily torsioned than one with a smaller number of longer struts 5. A related result is that, because torsionally induced strains are reduced, any tendency toward fatigue failure caused by torsional motions in-vivo is also reduced. - Flexibility and Bending Fatigue Resistance
- In the same way as torsional flexibility and fatigue resistance is improved by increasing the number of flexing elements, the flexural (or bending) flexibility and fatigue resistance are also improved. Bending of a
stent 1 causes adjacent turns or columns ofstruts 4 to be forced either toward each other (on the inside of a bend) or spread apart (on the outside of the bend). Because connectingbridges 8 join adjacent turns orcolumns 4, the local deformations caused by stent bending are spread over thestruts 5 and bending segments 7 (the 180-degree loops that join the ends of struts) between the connecting bridges 8. Thus, the more elements (struts 5 and bending segments 7) that exist between the connectingbridges 8, the greater number of elements there are to absorb the deformations caused by stent bending. Also, in a configuration withshorter struts 5, there is a greater number of turns orcolumns 4 acted upon by bending thestent 1, so the total number of elements deformed by bending thestent 1 is further increased, resulting in much smaller deformations to each of the elements. As deformations are reduced and strut widths are reduced, the effective strains in the stent material are significantly reduced, resulting in much improved fatigue resistance. - Enhanced Surface Area for Drug Elution
- The large number of
struts 5 of shorter length in astent 1 made according to the teachings of the present invention has greater surface area. For example, astent 1 according to the present teachings will have over twice as much kerf length than an otherwise similar prior art stent with half as many struts around the circumference. In self-expanding stents, kerf area (the area of the cut radial faces of the stent's elements) is the major contributor to total surface area because the area of the inner and outer surfaces is relatively smaller, due to the high aspect ratio (thickness to width) of the struts. Thus, the total surface area of astent 1 made according to the present teachings is substantially larger than that of a stent made according to prior-art configurations and, thus, it provides a larger surface area on which to apply medicated coatings. This larger surface area allows virtually all tissue within the coverage area of the stent to be in the drug elution areas. In particular, the stent provides tissue coverage so that no element of wall tissue is more than 350 microns to 400 microns away from the nearest strut. Such a configuration assures a short diffusion path from a strut covered with a drug-eluting agent to any portion of the tissue.
Claims (27)
1. A method for manufacturing a helical stent, which comprises:
providing a stent body with a circumference, with struts disposed about the circumference in turns, and with bridges connecting the struts in adjacent ones of the turns; and
after at least partially expanding the stent body, removing some of the bridges.
2. The method according to claim 1 , which further comprises forming the struts in a helix.
3. The method according to claim 1 , which further comprises carrying out the removing step by polishing and cleaning the stent body in processes selected from at least one of the group consisting of chemical, mechanical, and electrochemical.
4. The method according to claim 1 , which further comprises carrying out the removing step by polishing and cleaning the stent body in processes selected from at least one of the group consisting of abrasive blasting, glass-bead honing, chemical etching, mechanical polishing, electrochemical polishing, grinding, shearing, and cutting.
5. The method according to claim 1 , which further comprises, after carrying out the removing step, crimping the stent body onto a balloon catheter.
6. The method according to claim 1 , which further comprises, after carrying out the removing step, chilling the stent body and radially compressing the stent body.
7. The method according to claim 6 , which further comprises, after carrying out the radially compressing step, retaining the stent body in a compressed state for delivery to an implantation site.
8. The method according to claim 1 , which further comprises, after carrying out the removing step, radially compressing the stent body.
9. The method according to claim 8 , which further comprises, after carrying out the radially compressing step, retaining the stent body in a compressed state for delivery to an implantation site.
10. The method according to claim 1 , which further comprises providing the stent body with connecting bridges and sacrificial bridges each connecting the struts in adjacent ones of the turns.
11. The method according to claim 10 , which further comprises carrying out the removing step by partially removing all of the sacrificial bridges.
12. The method according to claim 10 , which further comprises carrying out the removing step by removing substantially all of the sacrificial bridges.
13. The method according to claim 10 , which further comprises carrying out the removing step to only have connecting bridges at the stent body thereafter.
14. The method according to claim 1 , which further comprises providing the stent body with a diameter of between approximately 4 mm and approximately 12 mm.
15. The method according to claim 1 , which further comprises providing the stent body with a length of between approximately 10 mm and approximately 250 mm.
16. The method according to claim 14 , which further comprises providing the stent body with a length of between approximately 10 mm and approximately 250 mm.
17. The method according to claim 1 , which further comprises providing the stent body with s-shaped struts disposed helically about the circumference along helical turns, the struts having straight portions and curved portions connecting at least some of respectively adjacent ones of the straight portions.
18. The method according to claim 1 , which further comprises providing the stent body with a finished kerf width of less than 25 microns.
19. The method according to claim 1 , which further comprises providing a stent body with a finished kerf width of approximately 18 microns.
20. The method according to claim 1 , which further comprises providing the stent body with a pre-cut tubing diameter of approximately 2 millimeters, with a post-cut number of struts per turn equal to 46, with a finished kerf width of approximately 18 microns, and with a post-cut strut width of 119 microns.
21. The method according to claim 1 , which further comprises:
providing the bridges with an initial curvature shape; and
controlling expansion of the stent body to substantially retain all of the initial curvature shape of the bridges.
22. A method for implanting a stent, which comprises:
providing a helical stent according to claim 1;
loading the stent at a stent delivery system;
traversing the stent at the delivery system to an implantation site; and
implanting the stent at the implantation site.
23. The method according to claim 22 , which further comprises carrying out the implantation step by implanting the stent in a blood vessel.
24. The method according to claim 22 , which further comprises carrying out the implanting step by expanding the stent at the implantation site.
25. The method according to claim 23 , which further comprises:
providing the stent as a balloon-expanding stent; and
expanding the stent with a balloon of a stent delivery system.
26. The method according to claim 22 , which further comprises:
providing the stent as a self-expanding stent; and
carrying out the implanting step by allowing the stent to self-expand at the implantation site.
27. The method according to claim 1 , which further comprises:
providing the bridges with an initial curvature shape; and
controlling expansion of the stent body to substantially retain all of the initial curvature shape of the bridges.
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/216,554 US20060064155A1 (en) | 2004-09-01 | 2005-08-31 | Stent and method for manufacturing the stent |
US11/216,222 US20060060266A1 (en) | 2004-09-01 | 2005-08-31 | Stent and method for manufacturing the stent |
MX2007002546A MX2007002546A (en) | 2004-09-01 | 2005-09-01 | Stent and method for manufacturing the stent. |
MX2007002536A MX2007002536A (en) | 2004-09-01 | 2005-09-01 | Stent and method for manufacturing the stent. |
EP05794073.6A EP1784267B1 (en) | 2004-09-01 | 2005-09-01 | Method for manufacturing a stent |
JP2007530450A JP2008511423A (en) | 2004-09-01 | 2005-09-01 | Stent and stent manufacturing method |
PCT/US2005/031556 WO2006026777A2 (en) | 2004-09-01 | 2005-09-01 | Stent and method for manufacturing the stent |
CA002578526A CA2578526A1 (en) | 2004-09-01 | 2005-09-01 | Stent and method for manufacturing the stent |
JP2007530451A JP2008511424A (en) | 2004-09-01 | 2005-09-01 | Stent and stent manufacturing method |
ES05794073.6T ES2664950T3 (en) | 2004-09-01 | 2005-09-01 | Method of making a stent |
CA002578102A CA2578102A1 (en) | 2004-09-01 | 2005-09-01 | Stent and method for manufacturing the stent |
EP05805038A EP1796590A2 (en) | 2004-09-01 | 2005-09-01 | Stent and method for manufacturing the stent |
PCT/US2005/031557 WO2006026778A2 (en) | 2004-09-01 | 2005-09-01 | Stent and method for manufacturing the stent |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60626104P | 2004-09-01 | 2004-09-01 | |
US11/216,554 US20060064155A1 (en) | 2004-09-01 | 2005-08-31 | Stent and method for manufacturing the stent |
US11/216,222 US20060060266A1 (en) | 2004-09-01 | 2005-08-31 | Stent and method for manufacturing the stent |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060060266A1 true US20060060266A1 (en) | 2006-03-23 |
Family
ID=42542826
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/216,554 Abandoned US20060064155A1 (en) | 2004-09-01 | 2005-08-31 | Stent and method for manufacturing the stent |
US11/216,222 Abandoned US20060060266A1 (en) | 2004-09-01 | 2005-08-31 | Stent and method for manufacturing the stent |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/216,554 Abandoned US20060064155A1 (en) | 2004-09-01 | 2005-08-31 | Stent and method for manufacturing the stent |
Country Status (6)
Country | Link |
---|---|
US (2) | US20060064155A1 (en) |
EP (2) | EP1796590A2 (en) |
JP (2) | JP2008511423A (en) |
CA (2) | CA2578102A1 (en) |
MX (2) | MX2007002536A (en) |
WO (2) | WO2006026778A2 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050202863A1 (en) * | 2004-03-15 | 2005-09-15 | Donna Macaulay | Ultimate Four of a Kind Bonus Poker |
US20060064155A1 (en) * | 2004-09-01 | 2006-03-23 | Pst, Llc | Stent and method for manufacturing the stent |
US20060064154A1 (en) * | 2004-09-01 | 2006-03-23 | Pst, Llc | Stent and method for manufacturing the stent |
US20060247759A1 (en) * | 2005-04-04 | 2006-11-02 | Janet Burpee | Flexible stent |
US20080215135A1 (en) * | 2005-02-17 | 2008-09-04 | Jacques Seguin | Device Allowing the Treatment of Bodily Conduits at an Area of a Bifurcation |
US20090306769A1 (en) * | 2008-06-06 | 2009-12-10 | Boston Scientific Scimed, Inc. | Medical balloon made with hybrid polymer-ceramic material and method of making and using the same |
US20100030324A1 (en) * | 2008-08-04 | 2010-02-04 | Jacques Seguin | Method for treating a body lumen |
US20110166641A1 (en) * | 2007-02-12 | 2011-07-07 | C.R. Bard Inc. | Highly flexible stent and method of manufacture |
US8038707B2 (en) | 2002-08-30 | 2011-10-18 | C.R. Bard, Inc. | Helical stent having improved flexibility and expandability |
US8070794B2 (en) | 2007-01-09 | 2011-12-06 | Stentys S.A.S. | Frangible bridge structure for a stent, and stent including such bridge structures |
US8226469B2 (en) | 2010-09-29 | 2012-07-24 | Igt | Gaming system, gaming device, and method for providing a poker game with a bonus gaming session having re-draw option |
US8333799B2 (en) | 2007-02-12 | 2012-12-18 | C. R. Bard, Inc. | Highly flexible stent and method of manufacture |
US20130158652A1 (en) * | 2009-05-20 | 2013-06-20 | Maria Palasis | Medical implants |
US8500794B2 (en) | 2007-08-02 | 2013-08-06 | Flexible Stenting Solutions, Inc. | Flexible stent |
US9149376B2 (en) | 2008-10-06 | 2015-10-06 | Cordis Corporation | Reconstrainable stent delivery system |
US9456911B2 (en) | 2006-02-14 | 2016-10-04 | Angiomed Gmbh & Co. Medizintechnik | Highly flexible stent and method of manufacture |
CN107714244A (en) * | 2017-10-26 | 2018-02-23 | 柏为(武汉)医疗科技股份有限公司 | Vein blood vessel is from swollen support |
US9907640B2 (en) | 2013-06-21 | 2018-03-06 | Boston Scientific Scimed, Inc. | Stent with deflecting connector |
US20180221057A1 (en) * | 2015-08-06 | 2018-08-09 | Syntec Corporation | Method for manufacturing medical linear member |
US10182928B2 (en) | 2013-04-16 | 2019-01-22 | Kaneka Corporation | Medical tubular body |
US10433987B2 (en) | 2002-08-30 | 2019-10-08 | C. R. Bard, Inc. | Highly flexible stent and method of manufacture |
US10568994B2 (en) | 2009-05-20 | 2020-02-25 | 480 Biomedical Inc. | Drug-eluting medical implants |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0020491D0 (en) | 2000-08-18 | 2000-10-11 | Angiomed Ag | Stent with attached element and method of making such a stent |
GB0609841D0 (en) | 2006-05-17 | 2006-06-28 | Angiomed Ag | Bend-capable tubular prosthesis |
GB0609911D0 (en) | 2006-05-18 | 2006-06-28 | Angiomed Ag | Bend-capable stent prosthesis |
GB0616999D0 (en) | 2006-08-29 | 2006-10-04 | Angiomed Ag | Annular mesh |
US8500793B2 (en) * | 2006-09-07 | 2013-08-06 | C. R. Bard, Inc. | Helical implant having different ends |
GB0622465D0 (en) | 2006-11-10 | 2006-12-20 | Angiomed Ag | Stent |
GB0624419D0 (en) | 2006-12-06 | 2007-01-17 | Angiomed Ag | Stenting ring with marker |
GB0706499D0 (en) | 2007-04-03 | 2007-05-09 | Angiomed Ag | Bendable stent |
US9265636B2 (en) * | 2007-05-25 | 2016-02-23 | C. R. Bard, Inc. | Twisted stent |
GB0717481D0 (en) | 2007-09-07 | 2007-10-17 | Angiomed Ag | Self-expansible stent with radiopaque markers |
US20090204203A1 (en) * | 2008-02-07 | 2009-08-13 | Medtronic Vascular, Inc. | Bioabsorbable Stent Having a Radiopaque Marker |
EP2493430B1 (en) | 2009-10-30 | 2020-12-02 | Cardinal Health Switzerland 515 GmbH | Intraluminal device with improved flexibility and durability |
US10285798B2 (en) * | 2011-06-03 | 2019-05-14 | Merit Medical Systems, Inc. | Esophageal stent |
EP2774585B1 (en) * | 2011-11-02 | 2016-07-06 | Nipro Corporation | Stent |
WO2014171183A1 (en) * | 2013-04-16 | 2014-10-23 | 株式会社カネカ | Medical tubular body |
CN112118812A (en) * | 2018-03-29 | 2020-12-22 | 萨哈詹德医疗技术私人有限公司 | Support frame |
CN114871590B (en) * | 2022-04-25 | 2023-12-22 | 杭州巴泰医疗器械有限公司 | Vascular stent laser cutting process |
Citations (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4886062A (en) * | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
US5314472A (en) * | 1991-10-01 | 1994-05-24 | Cook Incorporated | Vascular stent |
US5356423A (en) * | 1991-01-04 | 1994-10-18 | American Medical Systems, Inc. | Resectable self-expanding stent |
US5370683A (en) * | 1992-03-25 | 1994-12-06 | Cook Incorporated | Vascular stent |
US5421955A (en) * | 1991-10-28 | 1995-06-06 | Advanced Cardiovascular Systems, Inc. | Expandable stents and method for making same |
US5540712A (en) * | 1992-05-01 | 1996-07-30 | Nitinol Medical Technologies, Inc. | Stent and method and apparatus for forming and delivering the same |
US5569295A (en) * | 1993-12-28 | 1996-10-29 | Advanced Cardiovascular Systems, Inc. | Expandable stents and method for making same |
US5630829A (en) * | 1994-12-09 | 1997-05-20 | Intervascular, Inc. | High hoop strength intraluminal stent |
US5716393A (en) * | 1994-05-26 | 1998-02-10 | Angiomed Gmbh & Co. Medizintechnik Kg | Stent with an end of greater diameter than its main body |
US5741327A (en) * | 1997-05-06 | 1998-04-21 | Global Therapeutics, Inc. | Surgical stent featuring radiopaque markers |
US5776161A (en) * | 1995-10-16 | 1998-07-07 | Instent, Inc. | Medical stents, apparatus and method for making same |
US5780807A (en) * | 1994-11-28 | 1998-07-14 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for direct laser cutting of metal stents |
US5800520A (en) * | 1995-03-10 | 1998-09-01 | Medtronic, Inc. | Tubular endoluminar prosthesis having oblique ends |
US5810872A (en) * | 1997-03-14 | 1998-09-22 | Kanesaka; Nozomu | Flexible stent |
US5868781A (en) * | 1996-10-22 | 1999-02-09 | Scimed Life Systems, Inc. | Locking stent |
US5913897A (en) * | 1993-09-16 | 1999-06-22 | Cordis Corporation | Endoprosthesis having multiple bridging junctions and procedure |
US5935162A (en) * | 1998-03-16 | 1999-08-10 | Medtronic, Inc. | Wire-tubular hybrid stent |
US6013854A (en) * | 1994-06-17 | 2000-01-11 | Terumo Kabushiki Kaisha | Indwelling stent and the method for manufacturing the same |
US6042597A (en) * | 1998-10-23 | 2000-03-28 | Scimed Life Systems, Inc. | Helical stent design |
US6059808A (en) * | 1996-04-10 | 2000-05-09 | Laboratoires Nycomed Sa | Implantable device and delivery system to reestablish or maintain a bodily canal |
US6129755A (en) * | 1998-01-09 | 2000-10-10 | Nitinol Development Corporation | Intravascular stent having an improved strut configuration |
US6203568B1 (en) * | 1996-04-05 | 2001-03-20 | Medtronic, Inc. | Endoluminal prostheses having position indicating markers |
US6251135B1 (en) * | 1997-08-01 | 2001-06-26 | Schneider (Usa) Inc | Radiopaque marker system and method of use |
US6423091B1 (en) * | 2000-05-16 | 2002-07-23 | Cordis Corporation | Helical stent having flat ends |
US20020143386A1 (en) * | 2001-03-29 | 2002-10-03 | Davila Luis A. | Radiopacity intraluminal medical device |
US6475236B1 (en) * | 1997-02-07 | 2002-11-05 | Endosystems, Llc | Non-foreshortening intraluminal prosthesis |
US6485509B2 (en) * | 1998-03-04 | 2002-11-26 | Scimed Life Systems, Inc. | Stent having variable properties and method of its use |
US6537310B1 (en) * | 1999-11-19 | 2003-03-25 | Advanced Bio Prosthetic Surfaces, Ltd. | Endoluminal implantable devices and method of making same |
US20030074054A1 (en) * | 1998-01-09 | 2003-04-17 | Thomas Duerig | Intravascular device with improved radiopacity |
US6551351B2 (en) * | 1999-07-02 | 2003-04-22 | Scimed Life Systems | Spiral wound stent |
US20030093066A1 (en) * | 2001-09-10 | 2003-05-15 | Peyman Gholam A. | Ablatable intracorneal inlay with predetermined refractive properties |
US6572647B1 (en) * | 1999-10-29 | 2003-06-03 | Angiomed Gmbh & Co. Medizintechnik Kg | Method of making a stent |
US6585755B2 (en) * | 2001-06-29 | 2003-07-01 | Advanced Cardiovascular | Polymeric stent suitable for imaging by MRI and fluoroscopy |
US6613081B2 (en) * | 1997-11-14 | 2003-09-02 | Transvascular, Inc. | Deformable scaffolding multicellular stent |
US20030216807A1 (en) * | 2002-05-16 | 2003-11-20 | Jones Donald K. | Intravascular stent device |
US6660019B1 (en) * | 1994-10-27 | 2003-12-09 | Medinol Ltd. | Stent fabrication method |
US20040034402A1 (en) * | 2002-07-26 | 2004-02-19 | Syntheon, Llc | Helical stent having flexible transition zone |
US6976994B2 (en) * | 1997-10-01 | 2005-12-20 | Boston Scientific Scimed, Inc. | Flexible metal wire stent |
US7033385B2 (en) * | 2001-03-28 | 2006-04-25 | Boston Scientific Scimed, Inc. | Expandable coil stent |
US7037331B2 (en) * | 2001-06-14 | 2006-05-02 | Cordis Neurovascular, Inc. | Intravascular stent device |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5292331A (en) * | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
US5735892A (en) * | 1993-08-18 | 1998-04-07 | W. L. Gore & Associates, Inc. | Intraluminal stent graft |
US5549663A (en) * | 1994-03-09 | 1996-08-27 | Cordis Corporation | Endoprosthesis having graft member and exposed welded end junctions, method and procedure |
CA2147709C (en) * | 1994-04-25 | 1999-08-24 | Sharon S. Lam | Radiopaque stent markers |
DE69637527D1 (en) * | 1995-03-01 | 2008-06-26 | Boston Scient Scimed Inc | Longitudinally flexible and expandable stent |
US5591197A (en) * | 1995-03-14 | 1997-01-07 | Advanced Cardiovascular Systems, Inc. | Expandable stent forming projecting barbs and method for deploying |
RU2157146C2 (en) * | 1995-06-13 | 2000-10-10 | ВИЛЬЯМ КУК Европа, A/S | Device for performing implantation in blood vessels and hollow organs |
US5562697A (en) * | 1995-09-18 | 1996-10-08 | William Cook, Europe A/S | Self-expanding stent assembly and methods for the manufacture thereof |
US6719782B1 (en) * | 1996-01-04 | 2004-04-13 | Endovascular Technologies, Inc. | Flat wire stent |
US5895406A (en) * | 1996-01-26 | 1999-04-20 | Cordis Corporation | Axially flexible stent |
US5891191A (en) * | 1996-04-30 | 1999-04-06 | Schneider (Usa) Inc | Cobalt-chromium-molybdenum alloy stent and stent-graft |
US5925061A (en) * | 1997-01-13 | 1999-07-20 | Gore Enterprise Holdings, Inc. | Low profile vascular stent |
GB9703859D0 (en) * | 1997-02-25 | 1997-04-16 | Plante Sylvain | Expandable intravascular stent |
US5843175A (en) * | 1997-06-13 | 1998-12-01 | Global Therapeutics, Inc. | Enhanced flexibility surgical stent |
EP0890346A1 (en) * | 1997-06-13 | 1999-01-13 | Gary J. Becker | Expandable intraluminal endoprosthesis |
US5824059A (en) * | 1997-08-05 | 1998-10-20 | Wijay; Bandula | Flexible stent |
US6059822A (en) * | 1997-08-22 | 2000-05-09 | Uni-Cath Inc. | Stent with different mesh patterns |
NO311781B1 (en) * | 1997-11-13 | 2002-01-28 | Medinol Ltd | Metal multilayer stents |
US6022374A (en) * | 1997-12-16 | 2000-02-08 | Cardiovasc, Inc. | Expandable stent having radiopaque marker and method |
US6342067B1 (en) * | 1998-01-09 | 2002-01-29 | Nitinol Development Corporation | Intravascular stent having curved bridges for connecting adjacent hoops |
US6190406B1 (en) * | 1998-01-09 | 2001-02-20 | Nitinal Development Corporation | Intravascular stent having tapered struts |
US6533807B2 (en) * | 1998-02-05 | 2003-03-18 | Medtronic, Inc. | Radially-expandable stent and delivery system |
US6488701B1 (en) * | 1998-03-31 | 2002-12-03 | Medtronic Ave, Inc. | Stent-graft assembly with thin-walled graft component and method of manufacture |
US6019789A (en) * | 1998-04-01 | 2000-02-01 | Quanam Medical Corporation | Expandable unit cell and intraluminal stent |
US6755856B2 (en) * | 1998-09-05 | 2004-06-29 | Abbott Laboratories Vascular Enterprises Limited | Methods and apparatus for stenting comprising enhanced embolic protection, coupled with improved protection against restenosis and thrombus formation |
US6325820B1 (en) * | 1998-11-16 | 2001-12-04 | Endotex Interventional Systems, Inc. | Coiled-sheet stent-graft with exo-skeleton |
AU3370400A (en) * | 1999-02-26 | 2000-09-14 | Advanced Cardiovascular Systems Inc. | Stent with customized flexibility |
JP4518609B2 (en) * | 1999-03-05 | 2010-08-04 | テルモ株式会社 | Indwelling stent |
US6364903B2 (en) * | 1999-03-19 | 2002-04-02 | Meadox Medicals, Inc. | Polymer coated stent |
US6730116B1 (en) * | 1999-04-16 | 2004-05-04 | Medtronic, Inc. | Medical device for intraluminal endovascular stenting |
US6273911B1 (en) * | 1999-04-22 | 2001-08-14 | Advanced Cardiovascular Systems, Inc. | Variable strength stent |
US6245100B1 (en) * | 2000-02-01 | 2001-06-12 | Cordis Corporation | Method for making a self-expanding stent-graft |
US6352552B1 (en) * | 2000-05-02 | 2002-03-05 | Scion Cardio-Vascular, Inc. | Stent |
AU2001261801A1 (en) * | 2000-05-22 | 2001-12-03 | Orbus Medical Technologies Inc. | Self-expanding stent |
JP2002064157A (en) * | 2000-06-09 | 2002-02-28 | Toshiba Corp | Semiconductor memory integrated circuit and its manufacturing method |
US20050107738A1 (en) * | 2000-07-21 | 2005-05-19 | Slater Charles R. | Occludable intravascular catheter for drug delivery and method of using the same |
US20050113798A1 (en) * | 2000-07-21 | 2005-05-26 | Slater Charles R. | Methods and apparatus for treating the interior of a blood vessel |
US7037330B1 (en) * | 2000-10-16 | 2006-05-02 | Scimed Life Systems, Inc. | Neurovascular stent and method |
US6565599B1 (en) * | 2000-12-28 | 2003-05-20 | Advanced Cardiovascular Systems, Inc. | Hybrid stent |
US6955686B2 (en) * | 2001-03-01 | 2005-10-18 | Cordis Corporation | Flexible stent |
US6527938B2 (en) * | 2001-06-21 | 2003-03-04 | Syntheon, Llc | Method for microporous surface modification of implantable metallic medical articles |
US20030055485A1 (en) * | 2001-09-17 | 2003-03-20 | Intra Therapeutics, Inc. | Stent with offset cell geometry |
DE60213266T2 (en) * | 2001-10-09 | 2007-07-19 | William Cook Europe Aps | CANNULATED STENT |
US20040015229A1 (en) * | 2002-07-22 | 2004-01-22 | Syntheon, Llc | Vascular stent with radiopaque markers |
US7025777B2 (en) * | 2002-07-31 | 2006-04-11 | Unison Therapeutics, Inc. | Flexible and conformable stent and method of forming same |
US6878162B2 (en) * | 2002-08-30 | 2005-04-12 | Edwards Lifesciences Ag | Helical stent having improved flexibility and expandability |
DE10261822A1 (en) * | 2002-12-20 | 2004-07-01 | Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin | Helix bridge connection |
US7128752B2 (en) * | 2002-12-23 | 2006-10-31 | Syntheon, Llc | Emboli and thrombi filter device and method of using the same |
US6862794B2 (en) * | 2003-03-03 | 2005-03-08 | Medtronic Ave, Inc. | Method for manufacturing an endovascular support device |
US20060074480A1 (en) * | 2004-09-01 | 2006-04-06 | Pst, Llc | Stent and method for manufacturing the stent |
US20060064155A1 (en) * | 2004-09-01 | 2006-03-23 | Pst, Llc | Stent and method for manufacturing the stent |
US7771411B2 (en) * | 2004-09-24 | 2010-08-10 | Syntheon, Llc | Methods for operating a selective stiffening catheter |
-
2005
- 2005-08-31 US US11/216,554 patent/US20060064155A1/en not_active Abandoned
- 2005-08-31 US US11/216,222 patent/US20060060266A1/en not_active Abandoned
- 2005-09-01 MX MX2007002536A patent/MX2007002536A/en not_active Application Discontinuation
- 2005-09-01 EP EP05805038A patent/EP1796590A2/en not_active Withdrawn
- 2005-09-01 JP JP2007530450A patent/JP2008511423A/en active Pending
- 2005-09-01 JP JP2007530451A patent/JP2008511424A/en active Pending
- 2005-09-01 WO PCT/US2005/031557 patent/WO2006026778A2/en active Application Filing
- 2005-09-01 MX MX2007002546A patent/MX2007002546A/en not_active Application Discontinuation
- 2005-09-01 CA CA002578102A patent/CA2578102A1/en not_active Abandoned
- 2005-09-01 CA CA002578526A patent/CA2578526A1/en not_active Abandoned
- 2005-09-01 EP EP05794073.6A patent/EP1784267B1/en active Active
- 2005-09-01 WO PCT/US2005/031556 patent/WO2006026777A2/en active Application Filing
Patent Citations (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4886062A (en) * | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
US5356423A (en) * | 1991-01-04 | 1994-10-18 | American Medical Systems, Inc. | Resectable self-expanding stent |
US5314472A (en) * | 1991-10-01 | 1994-05-24 | Cook Incorporated | Vascular stent |
US5421955B1 (en) * | 1991-10-28 | 1998-01-20 | Advanced Cardiovascular System | Expandable stents and method for making same |
US5421955A (en) * | 1991-10-28 | 1995-06-06 | Advanced Cardiovascular Systems, Inc. | Expandable stents and method for making same |
US5514154A (en) * | 1991-10-28 | 1996-05-07 | Advanced Cardiovascular Systems, Inc. | Expandable stents |
US6066167A (en) * | 1991-10-28 | 2000-05-23 | Advanced Cardiovascular Systems, Inc. | Expandable stents |
US6485511B2 (en) * | 1991-10-28 | 2002-11-26 | Advanced Cardiovascular Systems, Inc. | Expandable stents and method for making same |
US5370683A (en) * | 1992-03-25 | 1994-12-06 | Cook Incorporated | Vascular stent |
US5540712A (en) * | 1992-05-01 | 1996-07-30 | Nitinol Medical Technologies, Inc. | Stent and method and apparatus for forming and delivering the same |
US5913897A (en) * | 1993-09-16 | 1999-06-22 | Cordis Corporation | Endoprosthesis having multiple bridging junctions and procedure |
US5649952A (en) * | 1993-12-28 | 1997-07-22 | Advanced Cardiovascular Systems, Inc. | Expandable stents and method for making same |
US5569295A (en) * | 1993-12-28 | 1996-10-29 | Advanced Cardiovascular Systems, Inc. | Expandable stents and method for making same |
US5716393A (en) * | 1994-05-26 | 1998-02-10 | Angiomed Gmbh & Co. Medizintechnik Kg | Stent with an end of greater diameter than its main body |
US5902317A (en) * | 1994-06-01 | 1999-05-11 | Nitinol Medical Technologies, Inc. | Stent and method and apparatus for forming and delivering the same |
US6013854A (en) * | 1994-06-17 | 2000-01-11 | Terumo Kabushiki Kaisha | Indwelling stent and the method for manufacturing the same |
US6660019B1 (en) * | 1994-10-27 | 2003-12-09 | Medinol Ltd. | Stent fabrication method |
US5780807A (en) * | 1994-11-28 | 1998-07-14 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for direct laser cutting of metal stents |
US5630829A (en) * | 1994-12-09 | 1997-05-20 | Intervascular, Inc. | High hoop strength intraluminal stent |
US5800520A (en) * | 1995-03-10 | 1998-09-01 | Medtronic, Inc. | Tubular endoluminar prosthesis having oblique ends |
US5776161A (en) * | 1995-10-16 | 1998-07-07 | Instent, Inc. | Medical stents, apparatus and method for making same |
US6203568B1 (en) * | 1996-04-05 | 2001-03-20 | Medtronic, Inc. | Endoluminal prostheses having position indicating markers |
US6059808A (en) * | 1996-04-10 | 2000-05-09 | Laboratoires Nycomed Sa | Implantable device and delivery system to reestablish or maintain a bodily canal |
US5868781A (en) * | 1996-10-22 | 1999-02-09 | Scimed Life Systems, Inc. | Locking stent |
US6475236B1 (en) * | 1997-02-07 | 2002-11-05 | Endosystems, Llc | Non-foreshortening intraluminal prosthesis |
US5810872A (en) * | 1997-03-14 | 1998-09-22 | Kanesaka; Nozomu | Flexible stent |
US5741327A (en) * | 1997-05-06 | 1998-04-21 | Global Therapeutics, Inc. | Surgical stent featuring radiopaque markers |
US6293966B1 (en) * | 1997-05-06 | 2001-09-25 | Cook Incorporated | Surgical stent featuring radiopaque markers |
US6251135B1 (en) * | 1997-08-01 | 2001-06-26 | Schneider (Usa) Inc | Radiopaque marker system and method of use |
US6976994B2 (en) * | 1997-10-01 | 2005-12-20 | Boston Scientific Scimed, Inc. | Flexible metal wire stent |
US6613081B2 (en) * | 1997-11-14 | 2003-09-02 | Transvascular, Inc. | Deformable scaffolding multicellular stent |
US20030074054A1 (en) * | 1998-01-09 | 2003-04-17 | Thomas Duerig | Intravascular device with improved radiopacity |
US6129755A (en) * | 1998-01-09 | 2000-10-10 | Nitinol Development Corporation | Intravascular stent having an improved strut configuration |
US6485509B2 (en) * | 1998-03-04 | 2002-11-26 | Scimed Life Systems, Inc. | Stent having variable properties and method of its use |
US5935162A (en) * | 1998-03-16 | 1999-08-10 | Medtronic, Inc. | Wire-tubular hybrid stent |
US6042597A (en) * | 1998-10-23 | 2000-03-28 | Scimed Life Systems, Inc. | Helical stent design |
US6551351B2 (en) * | 1999-07-02 | 2003-04-22 | Scimed Life Systems | Spiral wound stent |
US6572647B1 (en) * | 1999-10-29 | 2003-06-03 | Angiomed Gmbh & Co. Medizintechnik Kg | Method of making a stent |
US6537310B1 (en) * | 1999-11-19 | 2003-03-25 | Advanced Bio Prosthetic Surfaces, Ltd. | Endoluminal implantable devices and method of making same |
US6423091B1 (en) * | 2000-05-16 | 2002-07-23 | Cordis Corporation | Helical stent having flat ends |
US7033385B2 (en) * | 2001-03-28 | 2006-04-25 | Boston Scientific Scimed, Inc. | Expandable coil stent |
US20020143386A1 (en) * | 2001-03-29 | 2002-10-03 | Davila Luis A. | Radiopacity intraluminal medical device |
US7037331B2 (en) * | 2001-06-14 | 2006-05-02 | Cordis Neurovascular, Inc. | Intravascular stent device |
US6585755B2 (en) * | 2001-06-29 | 2003-07-01 | Advanced Cardiovascular | Polymeric stent suitable for imaging by MRI and fluoroscopy |
US20030093066A1 (en) * | 2001-09-10 | 2003-05-15 | Peyman Gholam A. | Ablatable intracorneal inlay with predetermined refractive properties |
US20030216807A1 (en) * | 2002-05-16 | 2003-11-20 | Jones Donald K. | Intravascular stent device |
US20040034402A1 (en) * | 2002-07-26 | 2004-02-19 | Syntheon, Llc | Helical stent having flexible transition zone |
US6969402B2 (en) * | 2002-07-26 | 2005-11-29 | Syntheon, Llc | Helical stent having flexible transition zone |
Cited By (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9554927B2 (en) | 2002-08-30 | 2017-01-31 | C.R. Bard, Inc. | Helical stent having improved flexibility and expandability |
US10433987B2 (en) | 2002-08-30 | 2019-10-08 | C. R. Bard, Inc. | Highly flexible stent and method of manufacture |
US10463509B2 (en) | 2002-08-30 | 2019-11-05 | C. R. Bard, Inc. | Helical stent having improved flexibility and expandability |
US8512391B2 (en) | 2002-08-30 | 2013-08-20 | C. R. Bard, Inc. | Helical stent having struts in a transition zone that progressively increase in length |
US8038707B2 (en) | 2002-08-30 | 2011-10-18 | C.R. Bard, Inc. | Helical stent having improved flexibility and expandability |
US20050202863A1 (en) * | 2004-03-15 | 2005-09-15 | Donna Macaulay | Ultimate Four of a Kind Bonus Poker |
US9064382B2 (en) | 2004-03-15 | 2015-06-23 | Igt | Gaming system and method for providing a poker game |
US8444465B2 (en) | 2004-03-15 | 2013-05-21 | Igt | Ultimate four of a kind bonus poker |
US7763067B2 (en) | 2004-09-01 | 2010-07-27 | C. R. Bard, Inc. | Stent and method for manufacturing the stent |
US10342685B2 (en) | 2004-09-01 | 2019-07-09 | Angiomed Gmbh & Co. Medizintechnik Kg | Stent and method for manufacturing the stent |
US20060064155A1 (en) * | 2004-09-01 | 2006-03-23 | Pst, Llc | Stent and method for manufacturing the stent |
US7780721B2 (en) | 2004-09-01 | 2010-08-24 | C. R. Bard, Inc. | Stent and method for manufacturing the stent |
US9486339B2 (en) | 2004-09-01 | 2016-11-08 | Angiomed Gmbh & Co. Medizintechnik Kg | Stent and method for manufacturing the stent |
US20060064154A1 (en) * | 2004-09-01 | 2006-03-23 | Pst, Llc | Stent and method for manufacturing the stent |
US10864095B2 (en) | 2004-09-01 | 2020-12-15 | Angiomed Gmbh & Co. Medizintechnik Kg | Stent and method for manufacturing the stent |
US20060064158A1 (en) * | 2004-09-01 | 2006-03-23 | Pst, Llc | Stent and method for manufacturing the stent |
US9192492B2 (en) | 2005-02-17 | 2015-11-24 | Jacques Seguin | Device allowing the treatment of bodily conduits at an area of a bifurcation |
US20080215135A1 (en) * | 2005-02-17 | 2008-09-04 | Jacques Seguin | Device Allowing the Treatment of Bodily Conduits at an Area of a Bifurcation |
US20060247759A1 (en) * | 2005-04-04 | 2006-11-02 | Janet Burpee | Flexible stent |
US7803180B2 (en) | 2005-04-04 | 2010-09-28 | Flexible Stenting Solutions, Inc. | Flexible stent |
US9592137B2 (en) | 2005-04-04 | 2017-03-14 | Flexible Stenting Solutions, Inc. | Flexible stent |
US11103371B2 (en) * | 2006-02-14 | 2021-08-31 | Angiomed Gmbh & Co. Medizintechnik Kg | Highly flexible stent and method of manufacture |
US10390978B2 (en) | 2006-02-14 | 2019-08-27 | Angiomed Gmbh & Co. Medizintechnik Kg | Highly flexible stent and method of manufacture |
US9456911B2 (en) | 2006-02-14 | 2016-10-04 | Angiomed Gmbh & Co. Medizintechnik | Highly flexible stent and method of manufacture |
US8070794B2 (en) | 2007-01-09 | 2011-12-06 | Stentys S.A.S. | Frangible bridge structure for a stent, and stent including such bridge structures |
US8333799B2 (en) | 2007-02-12 | 2012-12-18 | C. R. Bard, Inc. | Highly flexible stent and method of manufacture |
US8328865B2 (en) | 2007-02-12 | 2012-12-11 | C. R. Bard, Inc. | Highly flexible stent and method of manufacture |
US20110166641A1 (en) * | 2007-02-12 | 2011-07-07 | C.R. Bard Inc. | Highly flexible stent and method of manufacture |
US8500794B2 (en) | 2007-08-02 | 2013-08-06 | Flexible Stenting Solutions, Inc. | Flexible stent |
US20090306769A1 (en) * | 2008-06-06 | 2009-12-10 | Boston Scientific Scimed, Inc. | Medical balloon made with hybrid polymer-ceramic material and method of making and using the same |
US9005274B2 (en) | 2008-08-04 | 2015-04-14 | Stentys Sas | Method for treating a body lumen |
US20100030324A1 (en) * | 2008-08-04 | 2010-02-04 | Jacques Seguin | Method for treating a body lumen |
US10010438B2 (en) | 2008-10-06 | 2018-07-03 | Flexible Stenting Solutions, Inc. | Reconstrainable stent delivery system |
US9149376B2 (en) | 2008-10-06 | 2015-10-06 | Cordis Corporation | Reconstrainable stent delivery system |
US8992601B2 (en) * | 2009-05-20 | 2015-03-31 | 480 Biomedical, Inc. | Medical implants |
US20130158652A1 (en) * | 2009-05-20 | 2013-06-20 | Maria Palasis | Medical implants |
US10617796B2 (en) | 2009-05-20 | 2020-04-14 | Lyra Therapeutics, Inc. | Drug eluting medical implant |
US10568994B2 (en) | 2009-05-20 | 2020-02-25 | 480 Biomedical Inc. | Drug-eluting medical implants |
US8535135B2 (en) | 2010-09-29 | 2013-09-17 | Igt | Gaming system, gaming device, and method for providing a poker game with a bonus gaming session having re-draw option |
US8226469B2 (en) | 2010-09-29 | 2012-07-24 | Igt | Gaming system, gaming device, and method for providing a poker game with a bonus gaming session having re-draw option |
US10182928B2 (en) | 2013-04-16 | 2019-01-22 | Kaneka Corporation | Medical tubular body |
US9907640B2 (en) | 2013-06-21 | 2018-03-06 | Boston Scientific Scimed, Inc. | Stent with deflecting connector |
US10864069B2 (en) | 2013-06-21 | 2020-12-15 | Boston Scientific Scimed, Inc. | Stent with deflecting connector |
US20180221057A1 (en) * | 2015-08-06 | 2018-08-09 | Syntec Corporation | Method for manufacturing medical linear member |
US10864018B2 (en) * | 2015-08-06 | 2020-12-15 | Syntec Corporation | Method for manufacturing medical linear member |
CN107714244A (en) * | 2017-10-26 | 2018-02-23 | 柏为(武汉)医疗科技股份有限公司 | Vein blood vessel is from swollen support |
Also Published As
Publication number | Publication date |
---|---|
CA2578102A1 (en) | 2006-03-09 |
CA2578526A1 (en) | 2006-03-09 |
MX2007002546A (en) | 2007-08-02 |
JP2008511423A (en) | 2008-04-17 |
MX2007002536A (en) | 2007-05-09 |
WO2006026778A3 (en) | 2007-11-22 |
WO2006026777A2 (en) | 2006-03-09 |
WO2006026778A2 (en) | 2006-03-09 |
WO2006026777A3 (en) | 2009-04-16 |
EP1796590A2 (en) | 2007-06-20 |
EP1784267B1 (en) | 2018-03-21 |
US20060064155A1 (en) | 2006-03-23 |
JP2008511424A (en) | 2008-04-17 |
EP1784267A2 (en) | 2007-05-16 |
EP1784267A4 (en) | 2017-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10864095B2 (en) | Stent and method for manufacturing the stent | |
EP1784267B1 (en) | Method for manufacturing a stent | |
US10543114B2 (en) | Implants having high fatigue resistance, implant delivery systems, and methods of use | |
ES2664950T3 (en) | Method of making a stent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PST, LLC, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BALES, THOMAS O.;SLATER, CHARLES R.;JAHRMARKT, SCOTT L.;REEL/FRAME:017434/0985;SIGNING DATES FROM 20051114 TO 20051214 |
|
AS | Assignment |
Owner name: ANGIOMED GMBH & CO. MEDIZINTECHNIK KG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PST, LLC;REEL/FRAME:017285/0524 Effective date: 20060113 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |